









The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 











MOLECULAR ANALYSIS OF DECAY 
ACCELERATING FACTOR AS A POTENTIAL 
SUSCEPTIBILITY FACTOR TO DEVELOPING 
TREATMENT RESISTANT EXTRAOCULAR 











A thesis submitted to the University of Cape Town in fulfillment of the 















I, Henriette Uwimpuhwe, hereby declare that the work on which this thesis is 
based is my original work (except where acknowledgements indicate otherwise) 
and that neither the whole work nor any part of it has been, is being, or is to be 
submitted for another degree in this or any other university. I empower the 
University to reproduce for the purpose of research either the whole or any 
















I would like to express my sincere thanks to: 
• My supervisor Associate Professor Jeannine Heckmann whose help, support and 
guidance has meant so much throughout my research.  
• My co-supervisor Dr Robea Ballo for listening and teaching me so much in the 
laboratory. I am very grateful for her kindness, friendship and availability 
whenever I needed her. Thanks are also due to her for helping with the writing of 
this thesis. 
• My co-supervisor Dr Sharon Prince for her patience, encouragement and the 
much appreciated help with laboratory experiments.  
• The T-Box lab, especially Shaheen, Deeya, Emily, Sabina and Jade for always 
willing to help and enlightening up the days with laughter. 
• Dr Amaal Abrahams for her invaluable advice in the writing of this thesis. 
• Dr Huajian Tang for doing the site directed mutagenesis and helping me with 
some of the experiments. 
• Ms Ingrid Baumgarten for her kindness and willingness to help in preparation of 
the EBV-transformed cell lines. 
• Victoria van Kets for being such a friendly companion. 
• My loving family whom I miss very much, my dad Jonathan, Marthe, Henri, Alida 
and Edmond for always encouraging me and calling every week to check on me. 
So much of what I have achieved I owe it to you. 
• Vincent for your love, support and friendship, especially for always being there to 
listen and comforting me when I needed it. 
• My friends outside the lab, Delphine, Josiane, Chiedza, and Lumbidzani for their 
friendship and moral support. 
• International Brain Research Organization’s Levi Montalcini Fellowship for 
sponsoring me. I would also like to thank Muscular Dystrophy Association of 
South Africa and the University of Cape Town for supporting this research. 
• Last but not least, God Almighty for never leaving my side and for the good 











TABLE OF CONTENTS  
Student declaration         ii 
Acknowledgements         iii 
Table of content         iv 
List of figures         viii 
List of tables          x 
Abbreviations         xi 
Abstract          xiv 
CHAPTER 1: Literature review       1 
1.1 Myasthenia gravis       1 
1.2 The neuromuscular junction and susceptibility  
of the extraocular muscle      2 
1.3 The complement system and relevance to MG   4 
1.4 Complement regulatory proteins     6 
1.4.1 Structure and function of CRPs    6 
1.4.2 Comparison between human and mouse CRPs  8 
1.5 Decay accelerating factor (DAF)     8 
1.5.1 Structure and function of DAF    9 
1.5.2 Regulation of DAF gene expression   11 
1.5.3 Relevance of DAF in other disorders   12 
1.6 Background relevant to this study     13 
1.7 Association studies       13 
1.8 Study objectives       14 
 
CHAPTER 2: Materials and Methods      16 
2.1 Decay accelerating factor (DAF) genotying   16 
2.1.1 Subpopulations of patients and controls   16 
2.1.2 Primer designing      16 
2.1.3 Measuring DNA concentration    18 











2.1.5 Agarose gel electrophoresis    19 
2.1.6 Sequencing       20 
2.1.7 Statistical analysis      20 
2.2 Amplification of DNA constructs     21 
2.2.1 Plasmid constructs      21 
2.2.2 Making competent cells     21 
2.2.3 Ampicillin agar plates     21 
2.2.4 Transformation      22 
2.2.5 Large scale preparation of plasmid DNA   22 
2.3 Cell culture conditions and treatments    23 
2.3.1 Medium preparation      23 
2.3.2 Cell culture       23 
2.3.3 Mycoplasma test      23 
2.3.4 Transient transfection     24 
2.3.5 Luciferase assays      24 
2.3.6 Epstein Barr virus (EBV) transformation of 
 B-lymphocytes      25 
2.3.7 Lipopolysaccharide (LPS) treatment of cells  26 
2.4 Western blot analysis      26 
2.4.1 Protein extraction      26 
2.4.2 Protein quantification     27 
2.4.3 Sodium-dodecyl-sulphate polyacrylamide gel  
electrophoresis (SDS-PAGE)    28 
2.4.4 Protein transfer      28 
2.4.5 Western blot detection     29 
2.4.6 Stripping nitrocellulose membranes   30 
2.5 DAF gene mRNA expression analysis by quantitative  
real-time PCR       30 
2.5.1 RNA extraction from whole blood    30 
2.5.2 RNA extraction from lymphoblastoid cell lines  31 











2.5.4 Reverse transcription     32 
2.5.5 Quantitative real-time PCR (qRT-PCR)   33 
2.5.6 Quantification of mRNA and establishing  
the standard curves      35 
2.6 Transcription factor binding site (TFBS) analysis  37 
 
CHAPTER 3: Result        38 
3.1 Two SNPs were found in the 5` upstream region of the  
DAF gene        38 
3.2 The c.-198C>G SNP is more prevalent in the  
African genetic ancestry individuals and is more  
associated with the severe EOM MG phenotype  41 
3.3 The c.-198C>G affects basal DAF promoter activity  45 
3.4 The c.-198C>G does not appear to have any effect on  
endogenous DAF mRNA expression levels in the  
human lymhpocytes       51 
3.5 The c.-198C>G increases endogenous DAF mRNA  
level in lymphoblastoid cell lines     56 
3.6 There is a possible loss of a putative Sp1 transcription  
factor as a results of the c.-198C>G SNP   58 
3.7 The DAF regulatory region c.-198C>G SNP  
influences the lipopolysaccharide (LPS-) induced DAF  
up-regulation        61 
3.8 Brief summary of the results     63 
 
CHAPTER 4: Discussion        64 
4.1 A c.-198C>G SNP associates with the severe EOM  
phenotype in MG       65  
4.2 Regulatory effect of the DAF c.-198C>G SNP   66 
4.3 Loss of Sp1 site affects LPS-induced DAF upregulation  











4.4 Limitations to the study      71 
4.5 Conclusion        71 
        
REFERENCES         73 
 
APPENDIX A - General recipes and reagents     84 
APPENDIX B - Molecular weight markers     87 
APPENDIX C - Discarding of the lab waste     88 











List of Figures 
Figure 1.1: Structure of the neuromuscular junction    3 
Figure 1.2: Complement pathways, events and results of  
an activated complement system     5 
Figure 1.3: Structures of complement regulatory proteins,  
human DAF, MCP, CR1, CD59 and mouse Crry  7 
Figure 1.4A: Schematic diagram showing isoforms of the human DAF 
 gene, namely gDAF, sDAF, vDAF1, vDAF2 and vDAF3 10 
Figure 1.4B: Schematic diagram of the domain structures   10 
Figure 1.5: Photograph of MG patient with severe eye involvement  13 
Figure 2.1: CCDS 31006.1 sequence obtained from  
CCDS Database, NCBI      17 
Figure 3.1: Bands of approximately 500 bp of the DAF promoter  
were PCR-amplified as shown by the photograph of  
a 2% agarose gel       39  
Figure 3.2: Sequencing electropherograms showing the position  
where the c.-244_-243insA occurred    40  
Figure 3.3: Sequencing electropherograms of part of the DAF promoter  
region showing the position of the c.-198C>G SNP  40 
Figure 3.4: Dose curve to determine the amount of plasmid DNA  
to be used in transient transfections    46 
Figure 3.5: Effect of c.-198 C>G SNP on DAF promoter in COS 7  
(A and B) and HT1080 (C and D) cells    47 
Figure 3.6: 48-hour differentiated C2C12 cells     49 
Figure 3.7: Luciferase activity in C2C12 (Mouse myoblasts) cells  50 
Figure 3.8A: Amplification curves of DAF mRNA from the peripheral  
blood lymphocytes of the MG patients and normal controls 53 
Figure 3.8B: For the melting curve, temperature is plotted against the  
change in fluorescence with time.     53 
Figure 3.9: 2% agarose gel picture      54 











of data of the DAF mRNA expression in both  
patients (n = 11) and controls (n = 6).    55 
Figure 3.11: DAF expression in EBV transformed lymphoblastoid  
cell lines        57 
Figure 3.12: Nucleotide sequences of part of the DAF promoter region  
showing a total of 248 nucleotides from the initiation  
ATG start codon in the human DAF gene   59 
Figure 3.13: Effect of Sp1 transcription factor on the WT-DAF and the  
Mut-DAF        60 
Figure 3.14: LPS treatment did not upregulate DAF expression in  












List of Tables 
Table 2.1: The total number of patients and controls screened in the  
three racial groups of patients and controls.   16  
Table 2.2: Primer sequences (sense and antisense) used to amplify  
the different regions of the DAF gene    18 
Table 2.3: Summary of the optimized PCR reaction mixture set  
up for DAF gene amplification     19  
Table 2.4: Concentrations used to prepare the protein lysis buffer  27  
Table 2.5: Components of the Improm-II Reverse Transcription  
System used in the reaction.     33 
Table 2.6: Summary of optimized real time PCR parameters  
used for amplification of gDAF, GUS, GAPDH genes  34 
Table 2.7: Summary of real time PCR optimal cyclic conditions  
used for the gDAF       35 
Table 2.8: Summary of RT-PCR optimal cyclic conditions used  
for the GUS and GAPDH      35 
Table 3.1: Comparison of c.-244_-243insA allelic frequency and (%)  
within the MG patients and controls    42 
Table 3.2: Comparison of the allelic frequency in individuals (%)  
with the c.-198C>G in the MG patients and controls  43 
Table 3.3: Association of the c.-198C>G SNP with treatment-resistant  
         EOM involvement in South African MG subpopulation  44 
Table 3.4: The clinical characteristics of the MG patients used  













%  percentage 
ºC  degree celcius 
µg  microgram 
µl  microlitre 
µm  micrometre 
µM  micromolar 
ACh  acetylcholine 
AChR  acetylcholine receptor 
Af-Amer African-American 
APS  ammonium persulphate 
BCA  Bicichoninic acid 
BLAST basic local alignment search tool 
bp  basepairs 
BSA  bovine serum albumin 
C  controls 
CaCl2  calcium chloride 
cDNA  complementary DNA 
cm  centimetre 
cm2  square centimetre  
CO2  carbon dioxide 
CRP  complement regulatory proteins 
CT  crossing point 
DAF  decay accelerating factor 
DTT  dithiothreitol 
dbSNP  SNP database 
DLR  Dual Luciferase Reporter 
DMEM Dulbecco’s modified eagle’s medium 
DNA  deoxyribonucleic acid 
dH2O  distilled water 
dNTPs  deoxynucleotide triphosphates 
E  efficiency 
EAMG experimental autoimmune myasthenia gravis 
EBV  Epstein-Barr virus 
EDTA  ethylenediaminetetra-acetic acid 
FCS  foetal calf serum 
EOM  extraocular muscle 
fwd  forward 
g  gram 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
gDAF  GPI-anchored DAF 
GPI  glycosylphosphatidylinositol 
GSPEC gDAF- specific 
GUS  glucuronidase B 











HS  horse serum 
kb  kilobase 
KCl  potassium chloride 
kDa  kilodalton 
L  litre 
LAR II  Luciferase assay reagent II 
LB  Luria broth 
LCL  lymphoblastoid cell line 
LPS  lipopolysaccharide 
M/A  mixed ancestry 
MAC  membrane-attack complex 
mg  milligram 
MG  myasthenia gravis 
MgCl2  magnesium chloride 
min  minute 
ml  millilitre 
mm  millimetre 
mM  millimolar 
mRNA messenger RNA 
Na+  sodium ion 
Mut  mutant 
MW  molecular weight marker 
NaHCO3 Sodium hydrogen carbonate 
NCBI  National Centre for Biotechnology Information 
ng  nanogram 
NMJ  neuromuscular junction 
OD  optical density 
PBS  phosphate buffered solution 
PCR  Polymerase Chain reaction 
PHA  phytohaemagglutinin 
pmol  picamole 
P/S  Penicillin- Streptomycin 
qRT-PCR quantitative real-time PCR 
rev  reverse 
RNA  ribonucleic acid 
rpm  resolutions per minute 
SA  South Africa 
SANBI South African National Bioinformatics 
sDAF  soluble DAF 
SDS  sodium dodecyl sulphate 
SDS-PAGE SDS- polyacrylamide gel electrophoresis 
sec  second 
SNP  single nucleotide polymorphism 
STP  serine-threonine-proline 
Ta  annealing temperature 












TEMED NNN’N’- tetramethylethylenediamine 
Tm  melting temperature 
Tris  tris[hydroxymethyl]aminomethane 
U  unit 
UCT  University of Cape Town 
UK  United Kingdom 
USA  United State of America 
UV  ultraviolet 
UWC  University of Western Cape 
V  volts 













Myasthenia gravis (MG) is an autoimmune disorder in which auto-antibodies directed at 
the acetylcholine receptors (AChR) of the neuromuscular junction (NMJ) block, alter or 
destroy their targets. The anti-AChR antibodies cause activation of the classical 
complement pathway leading to inflammatory injury at the NMJ. Decay Accelerating 
Factor (DAF), a member of complement regulatory proteins, prevents activation of 
autologous components of complement pathways. The absence of DAF, in knock-out 
mouse models, has been shown to significantly increase the susceptibility to 
experimental autoimmune MG. A previous study showed that a high proportion of South 
African MG patients of African genetic ancestry develop immunosuppressive therapy-
resistant extraocular muscle (EOM) dysfunction. We hypothesized that these patients 
have deficient DAF expression in their EOMs resulting in less protection from 
complement injury. Sequence analysis of relevant regions of the DAF gene revealed a 
single nucleotide polymorphism (SNP), c.-198C>G, in the promoter region in MG 
patients of African genetic ancestry with severe EOM MG involvement (MG n=101; 
Control n= 132; Odds ratio= 6.6; p=0.009). DAF-luciferase reporter assays, using 3 
different cell lines (COS-7, HT1080 and C2C12) revealed that the c.-198C>G SNP (Mut-
DAF) led to an increase in DAF promoter activity (~ 2-fold) relative to that of the wild type 
(WT) sequence. Furthermore, quantitative real-time PCR performed on EBV transformed 
lymphoblastoid cell lines from four MG subjects with the c.-198C>G revealed an 
increase in the mRNA expression of membrane bound gDAF in the SNP cell lines 
compared to WT controls. Bioinformatic analyses revealed that the SNP led to the loss 
of a putative Sp1 transcription factor binding element within the promoter region of DAF. 
Co-transfections of either the WT- or Mut-DAF with pCMV-Sp1 and/or empty vector 
showed similar results suggesting that the putative Sp1 site lost by the SNP was not 
crucial for basal DAF regulation. However, the c.-198C>G SNP did not show the 
expected lipopolysaccharide (LPS)-induced DAF mRNA up-regulation in cell lines from 
four patients carrying this SNP. Results from this study therefore suggest that the c.-
198C>G associated with a severe EOM outcome in MG impairs normal transcriptional 
regulation of the DAF gene in response to an immune stress stimulus such as LPS.  The 
loss of the Sp1 binding site may result in inadequate upregulation of DAF expression at 
critical periods during the autoimmune response in MG with less protection of the EOM 











CHAPTER 1: LITERATURE REVIEW 
1.1 Myasthenia gravis 
Myasthenia gravis (MG) is an autoimmune disorder in which auto-antibodies are 
directed at the acetylcholine receptors (AChRs) at the neuromuscular junction 
(NMJ). This leads to neuromuscular transmission failure and weakness 
(Kaminski, 2003). MG was initially recognised in the 1600s when it was known as 
fatiguable weakness disorder (reviewed in Conti-Fine et al., 2006). The term 
myasthenia gravis was introduced in the late 1800s by combining the two Greek 
words of muscle and weakness, that is myasthenia, and adding the Latin word, 
gravis, which means severe (Keesey, 2002). 
MG is characterised by varying degrees of skeletal muscle weakness that 
increases during periods of activity and improves after periods of rest. The 
muscles that are usually affected include those controlling eye and eyelid 
movement, and limb movements. In addition, muscles that control breathing, 
chewing, swallowing, talking and facial expression may also be affected 
(reviewed in Conti-Fine et al., 2006). The extraocular muscles (EOMs) usually 
present as the initial symptom and in 90% of the patients the symptoms progress 
to other skeletal muscles mentioned. Therefore, MG is classified as ocular MG 
(when symptoms are limited to the EOMs) and generalized MG (symptoms are 
present in EOMs and other voluntary muscles) (reviewed in Conti-Fine et al., 
2006).  
Two types of MG exist, namely seropositive and seronegative. The 
majority of MG patients (85-90%) are seropositive as they possess antibodies 
against the AChRs at the NMJs (Bateman et al., 2005). Patients without 
detectable anti-AChR antibodies, however, are said to have seronegative MG 
and may have antibodies directed against other proteins found at the NMJ. The 
incidence rate of seropositive MG in South Africa is similar to that of other 
developing countries but is lower than that of developed countries. However, the 
incidence of seropositive MG in Cape Town, South Africa, was found to be 11.2 













2005). These results suggested underreporting in areas of South Africa where 
access to health care may be suboptimal (Bateman et al., 2005). 
Studies from both MG patients and experimental autoimmune MG 
(EAMG) in animals, showed that the AChR antibodies act by directly blocking the 
AChR function, accelerating AChR degradation, or initiating complement-
mediated damage at the NMJ (Zhou et al., 2007). The EAMG model was 
established in animals through immunization with purified solubilised AChR 
(Lennon et al., 1978) or by passive transfer of anti-AChR antibodies (Piddlesden 
et al., 1996).  
 
1.2 The neuromuscular junction and MG susceptibility of extraocular 
muscles 
The NMJ is the contact between the terminal nerve endings and the muscle 
fibres and lacks the protection that the blood-brain barrier provides for synapses 
in the central nervous system (Walton et al., 1994). The axon of each motor 
neuron divides into many branches as it approaches the synaptic bouton and 
each of these endings forms a NMJ with a single muscle fiber (Figure1.1). The 
terminal end of the axon contains synaptic vesicles that are filled with the 
neurotransmitter, acetylcholine (ACh), which is released when the action 
potential arrives at the axonal terminal. The postsynaptic membrane of the NMJ 
is highly folded and the AChRs are present on the crests of these folds. ACh 
diffuses across the synaptic cleft and attaches to the AChRs on the postsynaptic 
membrane causing the opening of the Na+ channels resulting in the initiation of 
depolarization along the muscle fibre.  
The NMJs of different muscles have varying properties and this may 
influence its susceptibility to MG (Hughes et al., 2006). For example, the NMJs of 
the EOMs, which control the movement of the eye, are more susceptible to MG 
than other muscles but the exact reason for this is still not clear. The EOMs 
constitute a unique group of six small skeletal muscles with a distinctive fiber 
type composition (Khanna et al., 2003). The NMJs of the EOMs are easily 













2004). These NMJs also have less prominent synaptic folds and fewer 
postsynaptic AChRs and Na+ channels (Khanna and Porter, 2002). It is also 
speculated that the NMJs of the EOM may be more susceptible to MG because 
they express less membrane-bound complement regulatory proteins compared 
to limb muscles hence less protection from complement-mediated damage 
(Kaminski et al., 2004; Conti-Fine et al., 2006).  
 
 
Figure1.1: Structure of the neuromuscular junction (NMJ). The axon of each 
motor neuron divides into many branches forming synaptic boutons and each of 
these endings forms a NMJ with a single muscle fiber. ACh diffuses across the 
synaptic cleft and attaches to the AChRs on the postsynaptic membrane causing 
the opening of the Na+ channels and initiates the depolarization along the 
















1.3 The complement system and relevance to MG 
The complement system is a cascade of biochemical reactions composed of over 
30 different serum and membrane proteins, which help to clear pathogens from 
the body and help the immune cells in fighting cancers and infections. This is 
done through cell lysis of pathogens, enhancement of phagocytosis and the 
attraction of inflammatory cells (Kohl, 2006; Walport, 2001). Complement can be 
activated by three different pathways, namely, the classical, alternative and lectin 
pathways (Figure 1.2). All three pathways lead to the formation of proteolytic 
enzymes known as C3 convertases, which mediate the cleavage of the C3 
protein into C3a and C3b (Kim and Song, 2006; Walport, 2001). This is followed 
by a series of activation steps and the generation of a number of proteins which 
lead to the formation of the membrane-attack complex (MAC) that causes cell 
destruction. 
In MG, the classical complement pathway is most relevant as it is 
activated by the pathogenic auto-antibodies attacking the AChRs on the 
postsynaptic membrane. Ultimately, this results in the formation of the MAC 
which leads to the damage of the postsynaptic surface of the muscle and 















Figure 1.2: Complement pathways, events and results of an activated 
complement system. There are three pathways involved in the complement 
system: classical, mannose-binding (MB)-lectin and alternative. The classical 
pathway is activated by antigen-antibody complex. For MG, the classical pathway 
is most relevant because of its activation by the antibodies that attack the 
acetylcholine receptors (AChRs). All three pathways converge on C3 resulting in 
its cleavage into C3a and C3b fragments. These proteins go through a series of 
events which leads to the formation of the membrane-attack complex (MAC) 
which is a common terminal pathway that causes cell lysis.  
 
There is ample evidence indicating that complement is the primary cause 
of damage at the NMJ in MG. Complement activation fragments C3, C9 and the 
MAC have been found at the NMJs in MG patients (Engel et al., 1979, Nakano 
and Engel, 1993; Sahashi et al., 1980, Fazekas et al., 1986). Furthermore, the 
C3 component was shown to be localised at the motor end-plate in animals with 
experimental autoimmune MG (EAMG), (Sahashi et al., 1978). In another study, 
cobra venom factor, known to prevent or reduce complement, was used to treat 
rats with EAMG (Lennon et al., 1978). Piddlesden et al. (1996) also showed that 
the potent complement regulatory molecule, soluble complement receptor 1, 













The complement system has to be tightly regulated to avoid damage of 
the body’s own cells. To prevent injury caused by activated complement a group 
of proteins known as complement regulatory proteins (CRPs), are ubiquitously 
expressed on the surfaces of almost all cell types (Miwa and Song, 2001; Kim 
and Song, 2006).  
 
1.4 Complement regulatory proteins (CRPs) 
Several CRPs have been characterized in humans including; decay accelerating 
factor (DAF) or CD55, a 70 kDa glycolipid-anchored membrane-bound protein 
which regulates complement activity by preventing the formation of C3 and C5 
convertases and accelerating their decay (Lublin and Atkinson, 1989); membrane 
cofactor protein (MCP) or CD46, which is a 60 kDa protein that mediates 
cleavage of C3b and C4b (Liszewski et al., 1991; Barilla-LaBarea et al., 2002); 
complement receptor 1 (CR1) or CD35, is a transmembrane receptor (190-280 
kDa)  that binds and processes C3b and C4b convertases (Ahern and Fearon, 
1989; Murray et al., 2000); CD59, also known as protectin, is a 18 to 20 kDa 
membrane-anchored protein that inhibits the formation of the terminal MAC on 
complement by binding to C8 and C9 and disrupting the C8:C9 ratio in the MAC 
(Okada et al., 1989; Rollins and Sims, 1990). Mice have also been shown to 
express a rare transmembrane protein complement-receptor 1-related 
gene/protein y (Crry) (Miwa and Song, 2001) (Figure 1.3) that has similar activity 
to that of MCP (Kim and Song, 2006).   
 
1.4.1 Structure and function of CRPs 
DAF and CD59 are attached to the cell membrane by a 
glycosylphopshatidylinositol (GPI)-anchor, whereas MCP, CR1 and Crry are 
inserted in the membrane via transmembrane domains (Miwa and Song, 2001; 















Figure 1.3: Structures of complement regulatory proteins, human DAF, MCP, 
CR1, CD59 and mouse Crry. DAF and CD59 are attached to the cell membrane 
by a glycosylphosphatidylinositol (GPI)-anchor, whereas MCP, CR1 and mouse 
Crry are attached via transmembrane domains. DAF and MCP have four 
complement control protein (CCP) domains and contain a STP-rich region 
between the CCP domains and the GPI-anchor or transmembrane domain (Kim 
and Song, 2006). 
 
Structurally, DAF, MCP, Crry and CR1 belong to a family of genes that 
regulates complement activation. They contain variable numbers of complement 
control protein (CCP) domains, also known as short consensus repeat domains. 
These CCP domains consist of approximately 70 amino acids with 4 conserved 
cysteine residues that form disulphide bonds (Kim and Song, 2006). DAF and 
MCP contain four CCP domains, human CR1 has 30 CCP domains and mouse 
Crry has five CCP domains (Miwa and Song, 2001) (Figure 1.3). CD59, the 
smallest protein of CRPs, does not contain any CCP domains, but its 
extracellular domain consists of approximately 70 amino acids with five 
disulphide bonds between the cysteine residues (Kim and Song, 2006) (Figure 













the GPI-anchor or transmembrane protein is present in DAF and MCP, 
respectively (Kim and Song, 2006) (Figure 1.3).  
 
1.4.2 Comparison between human and mouse CRPs 
A number of CRPs in humans correspond to those characterised in mice 
although several differences have been identified in the composition and 
expression patterns of their membrane CRPs (Miwa and Song, 2001). Crry is 
widely expressed in mice whereas MCP is restricted to the testis. Mice also differ 
from human in that their DAF and CD59 genes are duplicated into daf-1 and daf-
2, cd59a and cd59b genes, respectively (Spicer et al., 1995; Qian et al., 2000; 
Qin et al., 2001). Mouse daf-1 and cd59a, the human DAF and CD59 
homologues, are ubiquitously expressed and membrane-bound through their 
GPI-anchors (Figure 1.3), whereas daf-2 and cd59b are transmembrane proteins 
which are only expressed in the testis and splenic dendritic cells (Kaminski et al., 
2004; Harris et al., 2003). 
DAF is one of the CRPs that has been implicated in MG. Experiments 
done in mice showed that the Daf1 knockout mice with deficient neuromuscular 
Daf1 protein showed enhanced susceptibility to passively induced MG compared 
to control mice (Lin et al., 2002). CD59 has also been implicated in MG, however, 
mouse experiments have shown that DAF was more crucial in muscle protection 
against EAMG-associated complement injury (Kaminski et al., 2006). Daf1 knock 
out mice compared to their wild type littermates showed more susceptibility to 
EAMG induction and suffered more severe complement injury than the CD59 
knockout mice which showed minimal weakness compared to wild type 
(Kaminski et al., 2006; Lin et al., 2002).  
 
1.5 Decay accelerating factor (DAF) 
DAF or CD55 was first described in human erythrocytes by Hoffmann (1969) and 
was later isolated and characterised by Nicholson-Weller et al. (1982). The gene 













regulatory locus together with other complement regulating proteins (Lublin et al., 
1987). 
There are two major isoforms of DAF in humans, a 
glycosylphosphatidylinositol (GPI)-anchored form (gDAF), and a soluble form, 
sDAF (Medof et al., 1987), with five minor variants (Osuka et al., 2006). All these 
isoforms are generated from the same gene by alternative splicing (Caras et al., 
1989). The gDAF isoform is ubiquitously expressed on almost all peripheral 
blood cells (Kinoshita et al., 1985; Nicholson-Weller et al., 1985), epithelial and 
endothelial cells (Asch et al., 1986; Medof et al., 1987), unlike the sDAF which is 
expressed in the body fluids and extracellular matrix at much lower levels (Medof 
et al., 1987). 
The function of DAF is to protect host cells from activation of autologous 
complement on their surface. This is achieved by preventing the formation of 
new, and accelerating the decay of the classical and alternative C3 and C5 
convertases (Lublin and Atkinson, 1989; Nussewzweig, 1984). Previous studies 
have also identified DAF as a negative modulator of T cell immunity (Liu et al., 
2005; Heeger et al., 2005). DAF was also shown to have other noncomplement-
related functions, such as acting as a cellular ligand of CD97 (CD97-CD55) 
which is a member of the epidermal growth factor family (Hamann et al., 1996). 
The CD97-CD55 complex also appears to regulate T-cell effector function 
(Abbott et al., 2007). 
 
1.5.1 Structure and function of DAF 
The functional sites of DAF are contained within four N-terminal CCP domains 
encoded by exons 2 to 6 (Post et al., 1989) (Figure 1.4). The four CCPs are held 
above the surface of the membrane by the heavily glycosylated STP-rich stalk, 
encoded by exons 7, 8 and 9. The length of exons 7, 8 and 9 vary greatly, 
encoding 42, 27 and 7 amino acids, respectively, but approximately equal 
amounts of serine and threonine residues (40 to 44%) (Post et al., 1989). The 
soluble isoform, sDAF, differs from the GPI-anchored gDAF in that it includes 













and is found in bodily fluids and extracellular matrix (Medof et al., 1987). Three of 
the minor variants vDAF1, vDAF2 and vDAF3 include exons 11, 12 and 13 
respectively, and they lack the GPI-anchor just like the sDAF (Osuka et al., 
2006).   
 
Figure 1.4: A) Schematic diagram showing isoforms of the human DAF gene, 
namely gDAF, sDAF, vDAF1, vDAF2 and vDAF3. The boxes represent the exons 
of the DAF gene, showing that exons 2 to 6 encode for the CCP domains, exons 
7 to 9 encode for the STP rich domain and exons 10 to 14 encode the C-terminal 
region. The arrowheads below the boxes show the position of the stop codons in 
the cDNAs. B) Schematic diagram of the domain structures. Each domain is 
shown by a different pattern, which in turn corresponds to the exon with the same 
pattern. Adapted from Osuka et al., 2006. 
 
The anchorage of gDAF on the membrane is facilitated by the GPI anchor 













encodes the 3` untranslated region (Post et al., 1989). The GPI membrane 
attachment is directed by the carboxyl (COOH)-terminal signal, Serine-319, 
which is the cleavage site at the COOH-terminus (Caras, 1991).  
The remaining 2 minor variants, vDAF4 and vDAF5 contain either part of 
or the full intron 7 in their mRNA, and possess the GPI-anchor as the gDAF 
isoform (Osuka et al., 2006). The active sites of DAF for the classical and the 
alternative complement pathways are different (Coyne et al., 1992). It was shown 
by Coyne et al. (1992) using deletion constructs that the CCP1 did not affect the 
function of DAF on complement whereas the deletion of the CCP2, 3 and 4 
individually, completely abolished the function of DAF. In addition, it was shown 
that whereas inhibition of both the classical and the alternative pathways require 
the regulatory function of the CCP2 and 3 (Coyne et al., 1992; Brodbeck et al., 
1996; Brodbeck et al., 2000; Kuttner-Kondo et al., 2001), the CCP4 is necessary 
for the regulation of the alternative complement pathway function only. The STP-
rich region has been shown to prevent rapid proteolysis of the DAF molecule as it 
is heavily glycosylated and has a critical spacer function that holds DAF further 
away from the plasma membrane (Coyne et al., 1992).  
 
1.5.2 Regulation of DAF gene expression 
DAF expression has been shown to be modulated by cytokines, for example IL-1, 
IL-6, TNF-alpha, TGF-beta 1, IFN-gamma, prostaglandins and tissue-specific 
factors suggesting that regulation of DAF expression is tissue- and cell-type 
specific and affected by inflammation (reviewed in Cauvi et al., 2006). The 
primary regulation of DAF has been demonstrated to be at a transcriptional level 
(Thomas and Lublin, 1993; Kendall et al., 1996).  
The DAF promoter has been shown, in both human and mouse, to lack 
the TATA and CCAAT boxes (Thomas and Lublin, 1993; Cauvi et al., 2006) and 
to contain a GC-rich domain, which is a common feature of TATA-less promoters 
(reviewed in Cauvi et al., 2006). Furthermore, TATA-less promoters frequently 
contain several transcriptional start sites, as is the case for house-keeping genes 













Ewulonu et al. (1991) identified the main transcriptional start site of DAF to be 
located 82 bp upstream of the ATG codon, whereas Thomas and Lublin (1993) 
found several transcription start sites in a 10 bp region located 87 bp upstream of 
the ATG codon. Deletion analyses of the DAF promoter have shown that the 
promoter region contains both enhancer and repressor elements that influence 
the regulation of the DAF gene (Cauvi et al., 2006; Thomas and Lublin, 1993).  
 
1.5.3 Relevance of DAF in other disorders 
Several studies have implicated DAF in a number of inflammatory disorders 
although its exact role is not fully understood. Complement fragments, C3b, were 
detected at the site of injury in chronic inflammatory bowel diseases in humans 
(Halstensen et al., 1992; Ueki et al., 1996) possibly implicating reduced DAF 
expression. Individuals with the Cromer Inab phenotype of blood group antigens 
have been found to develop inflammatory bowel diseases due to polymorphisms 
within the DAF gene resulting in low or no DAF expression (Daniels et al., 1998; 
Tate et al., 1989; Lublin et al., 1994; Lin et al., 2004). This disorder results from 
complement injury to the gastrointestinal tract tissue cells (Lin et al., 2004). 
Experiments performed in an experimental model of inflammatory bowel disease 
also showed that DAF-deficient mice were more susceptible to epithelial injury in 
their distal colon induced by dextran sulfate sodium and had delayed tissue 
healing (Lin et al., 2004). Moreover, Miwa et al. (2007) also showed that DAF 
expression was particularly important in reducing local skin inflammation in the 
murine model of human systemic lupus erythematosus. 
 In paroxysmal nocturnal hemoglobinuria, patients have little or no 
membrane bound DAF or CD59 on their erythrocytes. In this acquired condition 
complement leads to the destruction of red blood cells in the blood stream due to 
a defect in the GPI anchor (Rosse and Nishimura, 2003; Yazer et al., 2006). 
Finally, DAF was also found to be down-regulated in individuals and mouse 
models with dysferlin-deficient muscular dystrophy (Wenzel et al., 2005). In this 
study it was shown that the reduced DAF expression led to increased 














1.6 Background relevant to this study 
The University of Cape Town-MG clinic has reported racial differences in the 
phenotype of MG and the response of these MG patients to standard 
immunosuppressive treatment (Heckmann et al., 2007). Proportionately more 
individuals of African ancestry developed a severe ocular phenotype 
characterised by treatment-resistant complete ophthalmoplegia and ptosis, in 
which all the EOMs and eyelids are paresed (Heckmann et al., 2007). Figure 1.5 
is a photograph of one of the patients with complete ophthalmoplegia and ptosis. 
In the present study we investigated whether these phenotypic differences were 
related to a reduction of DAF expression associated with genetic polymorphisms 
or mutations in the DAF molecule. It was hypothesised that DAF expression may 
be lower than normal or not properly upregulated during “inflammatory stress” 
resulting in inadequate complement protection in the EOM’s of the subgroup of 
MG patients tested. 
 
Figure 1.5: Photograph of MG patient with severe eye involvement (with 
permission from the patient) (Heckmann et al., 2007). 
 
 
1.7 Association studies 
Genetic association studies have been widely used to study whether genetic 
variants in populations contribute to the susceptibility of complex disorders 
(Campbell and Rudan, 2002). The rationale for genetic association studies is to 
determine whether a genetic variant, such as a single nucleotide polymorphism 













frequencies are different between case studies (diseased individuals) and 
healthy controls from the same population group (Rodriguez-Murillo and 
Greenberg, 2008). An association can be expected between a disease trait and a 
genetic variant if the variant either has a direct functional effect on the phenotype 
or if it is in linkage disequilibrium (LD) with a pathogenic mutation or functional 
polymorphism. LD is when two or more loci on a chromosome are more likely to 
segregate together in meiosis due to physical proximity to each other on a 
chromosome (Cardon and Bell, 2001; Rodriguez-Murillo and Greenberg, 2008). 
Once association of a genetic polymorphism has been established in one 
population it should be repeated in another (Campbell and Rudan, 2002) 
Experiments are then carried out to investigate the functional importance of the 
variants and how it relates to the phenotype (Luretta, 2008). A number of SNPs 
has been shown to play essential roles in susceptibility to several complex 
multifactorial disease traits, including type I diabetes and Graves’ autoimmune 
disease (Knight, 2004).  
The estimation of SNP allele frequencies is a simple and cost-effective 
approach in genetic association studies (Rodriguez-Murillo and Greenberg, 
2008). A difference in the allele frequencies of the SNP between the patients and 
the controls from the same population would indicate that the genetic marker 
may increase the likelihood of the disease trait, or be in LD with a disease 
causing SNP (Rodriguez-Murillo and Greenberg, 2008; Cardon and Bell, 2001).  
 
1.8 Study objectives 
The main objective of this study was to investigate the involvement of DAF in the 
increased susceptibility of African (or recent admixture) MG patients in the 
development of treatment resistant extra ocular muscle (EOM) paralysis.  
This was achieved by: 
I. Examining critical areas of the DAF gene for mutations in exons as well as 
the promoter region. 
II. Determining the functional importance of genetic change(s) by using site-
















III. Investigating whether the membrane-bound gDAF expression is altered in 
the peripheral blood lymphocytes and the lymphoblastoid cell lines from the 











CHAPTER 2: MATERIALS AND METHODS 
2.1 Decay-accelerating factor (DAF) genotyping 
2.1.1 Subpopulations of patients and controls  
This study was undertaken on 136 patients and 167 controls (Table 2.1). 
Unselected patients attending the UCT-MG clinic were invited to participate and 
after obtaining informed consent, EDTA blood for DNA extraction was collected. 
The severity of extra-ocular muscle (EOM) dysfunction (at rest) of the patients 
was assessed and quantified according to the scoring method described by 
Heckmann et al. (2007). Patients belonged to the White, Mixed-Ancestry (M/A) or 
Black subpopulations of South Africa. Whites are mostly of European origin, the 
Black subpopulation is composed of indigenous Black Africans while the M/A 
(also known as Coloured) subpopulation is composed of an admixture of 
European, African, Indian, Malay and Khoi San. Racially matched control DNA 
was taken from DNA samples collected during a previous study (Heckmann et 
al., 2001) with permission to use the samples for subsequent unrelated genetic 
studies, as approved by the UCT Research Ethics Committee permission. 
 
Table 2.1: The total number of patients and controls screened in the three racial 
groups of patients and controls  
 
 
2.1.2 Primer designing  
For mutation screening in genomic DNA using conventional PCR, oligonucleotide 
primers were designed to be intronic, flanking the exons and the intron/exon 











sequence, Genebank RefSeq-file NM_000574, in the human genome database 
(www.ncbi.nlm.nih.gov/entrez) and are listed in Table 2.2. Generally, the primers 
used were 18 to 26 nucleotides long, had 45 to 55% GC contents and the 
differences between melting temperatures of the sense and the antisense 
primers were less than 5ºC. Primers capable of being self-complementary or 
complementary to each other in the reaction mixture were avoided. 
For RNA expression analysis using quantitative real time PCR, primers were 
designed to specifically amplify the membrane-bound gDAF and exclude the 
other major isoform, sDAF, and the minor isoforms, vDAF 1 to 5. This was 
achieved by designing the primers so that the reverse primer spanned the exon 
9/ exon 14 junction as shown in the sequence below (Figure 2.1). This primer 
pair is referred to as Gspec (for gDAF-specific) and is shown in boxes in Figure 
2.1 which shows the Gspec forward primer (5’- 
GGATTCACCATGATTGGAGAGC- 3’) in exon 6 and the Gspec reverse primer 
(5’- TGTGCCCAGATAGAAGAC- 3’) spanning the exon 9 / exon 14 junction. The 
oligonucleotide primers for the house-keeping genes, glucuronidase B (GUS) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from 










Figure 2.1: CCDS 31006.1 sequence obtained from CCDS Database, NCBI. The 
blue and the black colours show the alternating exons. The forward (sense) 
primer is in exon 6 and the reverse (antisense) primer is at the exon 9/ exon 14 












Table 2.2: Primer sequences (sense and antisense) used to amplify the different 
regions of the DAF gene. 
 
 
2.1.3 Measuring DNA concentration  
The concentration of extracted DNA was measured using a NanoDrop ND-1000 
UV-visible spectrophotometer (NanoDrop Technologies, USA). The NanoDrop 
software displays the concentration in ng/µl and an estimation of the purity of 
DNA is assessed by 260/280 ratio. A ratio of 1.8 - 2.0 is accepted as pure for 
DNA.  
 
2.1.4 Conventional polymerase chain reaction (PCR) 
Genomic DNA was extracted from whole blood from patients and controls using 
the Genomic DNA purification kit (PUREGENE® DNA Purification System, Gentra 
Systems, USA) according to the manufacturer’s protocol. Generally, PCR was 
performed in a volume of 25 µl using 100 ng of template DNA and a final 
concentration of 10 pmol sense and antisense oligonucleotides, 200 µM dNTPs, 
1x Taq polymerase buffer, 1.5 mM MgCl2 and 0.1 – 1 U Taq DNA polymerase 
(Table 2.3).  
PCR was performed under the following conditions: initial denaturation at 
94°C (5 minutes) followed by 25 amplification cycles comprising denaturation at 
94°C (30 seconds), annealing at 60°C (30 seconds) temperature which varied 











regions of the DAF gene (Table 2.2), extension of 72°C (30 seconds), followed 
by a final extension at  72°C (7 minutes) in a 2720 Thermal Cycler (Applied 
Biosystems, USA). 
Some parameters were altered slightly in several PCR attempts, to 
optimize the PCR reactions. These included the initial amount of DNA template 
(50 ng – 200 ng), MgCl2 concentration (1.5 mM – 3 mM), the annealing 
temperature (50°C – 63°C), the type of commercial Taq Polymerase enzymes, 
GoTaq (Promega, USA) and BioTaq (Bioline Ltd, UK), and buffers (GoTaq, 
BioTaq and Failsafe (Epicentre Biotechnologies, USA)). 
 





2.1.5 Agarose gel electrophoresis 
The size of the amplified PCR product was checked by electrophoresis on a 2% 
agarose gel. A total volume of 8 µl of sample was loaded per well containing 5 µl 
of PCR product mixed with 3 µl of agarose loading dye. In this study, the loading 











ratio 1:2000 (appendix A), for visualization on a UV transluminator. A 100 bp 
molecular weight marker (appendix B) was loaded on each gel together with the 
PCR products.  
 
2.1.6 Sequencing 
PCR products were sequenced either in one or both forward and reverse 
directions, using the same oligonucleotides used for PCR amplification. The 
sequencing reactions were performed using the BigDye® terminator cycle version 
3.1 sequencing kit (Applied Biosystems, USA). Briefly, the reaction was 
composed of 10 µM of oligonucleotide, 1x reaction buffer, 2 µl of termination mix 
and 2 µl of PCR product in a total volume of 20 µl. The cycling conditions used 
were 96°C for 5 minutes followed by 25 cycles of 95°C for 30 seconds, 50°C for 
15 seconds and 60°C for 4 minutes.  
After the cycle sequencing reaction the products were cleaned by ethanol 
precipitation (Appendix A), air-dried then mixed with Hi-DiTM formamide (Applied 
Biosystems, USA) and heat denatured prior to electrophoresis on an acrylamide 
gel. The DNA sequences were read on the ABI PrismTM 3100 automated 
sequencer (Applied Biosystems, USA). Analysis was performed using ABITM 
DNA Sequencing Analysis Software version 3.7. The sequences obtained were 
also confirmed manually and analyzed for any changes by aligning them with the 
known reference sequence using the Clustal Alignment facility in BioEdit version 
7.0.0. 
 
2.1.7 Statistical analysis 
Allele and genotype frequencies were compared between groups using 2 x 2 
tables to obtain a Yates corrected Chi-square 2-tailed p-value; if a cell value was 
<5 the Fisher-exact test was used (http://www.openepi.com).  Odds ratios were 














2.2 Amplification of DNA constructs 
2.2.1 Plasmid constructs 
The decay accelerating factor (DAF) promoter region (-724 to +80) cloned as a 
Bgl II and Hind III fragment in the pGL3-basic firefly luciferase reporter vector 
was kindly donated by Ray DuBois (Holla et al., 2004) and will be referred to as 
WT-DAF throughout this thesis. Site directed mutagenesis was performed, using 
the WT-DAF reporter construct as a template, to mutate the C at position -198 to 
G (performed by Dr Huajiang Teng, UCT) and this construct will be called Mut-
DAF throughout this thesis. 
 
2.2.2 Making competent cells 
DH5αE. coli cells were inoculated into 5 ml of Luria Broth (LB) (appendix A) and 
incubated overnight at 37°C with shaking. One ml of this culture was then used to 
inoculate 100 ml of LB and cells grown for 2 to 3 hours until cell growth reached 
the log phase (OD595 = 0.6). Cells were centrifuged at 1800 x g for 10 minutes at 
room temperature (Centrifuge 5810R, Eppendorf, Germany); the bacterial pellet 
re-suspended in 100 mM Calcium chloride (CaCl2) solution and incubated on ice 
for 1 hour. Following centrifugation, the supernatant was discarded and 1 ml of 
CaCl2 was used to re-suspend the pellet. CaCl2 creates small holes in the cell 
wall of the bacteria that allow for the entry of foreign DNA but causes the cells to 
be very fragile and care was taken in successive processes so as not to 
permanently damage the cells. A 100 µl of competent cells were either used 
immediately for DNA transformation or they were frozen in autoclaved glycerol at 
-70°C for long term storage. 
 
2.2.3 Ampicillin agar plates 
All plasmids used in this study carried the ampicillin resistance gene. Ampicillin 
(50 µg/ml) was added to 1.5% bacterial agar (prepared in LB) which was poured 
into 10 cm dishes to a volume of 20 ml per dish. The agar was allowed to set at 













To a 100 μl of competent cells, 5 μl of DNA plasmid solution was added and then 
incubated on ice for 10 minutes. Cells were heat-shocked at 42°C for 1 minute, to 
allow the bacteria to take up the DNA constructs. Cells were then incubated on 
ice for 2 minutes, after which 300 μl of antibiotic-free LB was added and the cells 
incubated at 37°C for 1 hour while shaking gently. A volume of 200 μl was added 
to the ampicillin-containing agar plate and a bent Pasteur pipette was used to 
spread the mixture all over the plate. Plates were incubated at 37°C with the agar 
side down for 20 minutes, then inverted with the agar side up and left to grow 
overnight. A negative control plate containing un-transformed competent cells 
was included. No growth should be seen on the negative control plate as only 
cells carrying the ampicillin resistance-containing vector DNA should survive.  
 
2.2.5 Large scale preparation of plasmid DNA 
Single colonies were incubated in 5 ml of LB containing 50 µg/ml ampicillin and 
incubated at 37°C overnight with gentle shaking. One ml of the overnight culture 
was inoculated in 400 ml of ampicillin-containing LB in a 2 L flask and incubated 
overnight at 37°C with shaking. The PureYield Maxiprep System kit (Promega, 
USA), which makes use of a silica-membrane column filtration, was used 
following the manufacturer’s instructions to isolate high quality plasmid DNA. 
Briefly, cells were pelleted by centrifuging at 5,000 x g for 10 minutes and the 
pellet resuspended in 12 ml of supplied Cell Resuspension Solution which 
contains Tris- HCl (pH7.5), EDTA and RNase A. A volume of 12 ml of supplied 
Cell Lysis Solution was then added to the above and mixed together by gently 
inverting the tube several times. This was incubated for 3 minutes at room 
temperature to allow for cell lysis. Neutralization Solution was added to the lysed 
cells and the tube inverted several times so as to completely precipitate the 
cellular debris. Next, the lysate was centrifuged at 7000 x g for 30 minutes at 
room temperature in a fixed-angle rotor to pellet the bulk of the cellular debris. 
The DNA-containing lysate was passed through a filtration column using a 











membrane was then washed using ethanol-containing Column Wash and finally 
the required DNA eluted in 1 ml of Nuclease-Free water. DNA concentration was 
determined using the ND1000 Spectrophotometer (NanoDrop) together with the 
NanoDrop ND-1000 3.3 software (Coleman Technologies Inc).  
 
2.3 Cell culture conditions and treatments 
2.3.1 Medium preparation 
A day before the preparation of the medium, 2 bottles of 500 mls were 
autoclaved together with 1 L of distilled water and 1 L beaker with a stirrer bar 
covered with foil paper. The powdered Dulbecco’s Modified Eagle’s Medium 
(DMEM) and NaHCO3 were added to the autoclaved water while stirring until well 
dissolved and the pH adjusted to 7.2. The medium was immediately filter-
sterilized using a 0.22 μm filter and then aliquoted into the autoclaved 500 ml 
bottles and stored at 4°C. Medium older than 3 weeks was re-supplemented with 
L-glutamine because of its instability. 
 
2.3.2 Cell culture 
Cos 7 (Green monkey epithelial kidney), HT 1080 (human fibrosarcoma) and 
C2C12 (mouse myoblast) cells were cultured in DMEM, supplemented with 10% 
heat inactivated foetal calf serum (FCS) (Gibco, UK) and 1% Penicillin-
Streptomycin (P/S) antibiotics in a 37°C incubator (95% air, 5% CO2, 65% 
humidity). C2C12 cells were allowed to differentiate by switching from growth 
medium (DMEM + 10% FBS + 1% P/S) to differentiating medium (DMEM 
supplemented with 2% Horse serum and 1% P/S). All cultures were routinely 
subjected to mycoplasma tests and only mycoplasma free cells were used in 
experiments. 
 
2.3.3 Mycoplasma test 
Cells grown on a coverslip in antibiotic-free media for 2-3 days were fixed in a 1:3 
mixture of glacial acetic acid and methanol for 5 sec, washed briefly with water to 











DNA was stained with Hoechst 33258 (0.5 μg/ml) for 30 sec, washed briefly with 
water to remove excess stain and then mounted on a slide with mounting fluid at 
pH 5.5. The cells were viewed immediately by fluorescence microscopy under 
the DAPI filter. Mycoplasma negative cells stained positive with Hoechst 33258 
only in the nucleus, while cells infected with mycoplasma showed staining in both 
the nucleus and cytoplasm. 
 
2.3.4 Transient transfection 
Transfections were performed using FuGENE HD (Roche, USA) according to the 
manufacturer’s instructions. FuGENE is a lipid based reagent that aids delivery of 
DNA into mammalian cells. Cells were plated at 1.5 x 105 and grown to 70-80% 
confluence in 35 mm dishes before transfection with 1800 ng of a firefly 
luciferase reporter vector driven by either the wild type (WT-) DAF or the mutant 
(Mut-) DAF promoters. A pRL-TK vector which encodes for Renilla luciferase was 
included in each transfection to serve as an internal control of transfection 
efficiency. The cells were incubated for 48 hours and then harvested for 
luciferase assays. All transfections were done in duplicates. 
 For the C2C12 cells, differentiation was induced 6 hours post transfection 
by changing the medium to DMEM supplemented with 2% horse Serum and 1% 
P/S. The cells were then harvested and promoter activity measured after 48 and 
96 hours of differentiation.  
 
2.3.5 Luciferase assays 
The luciferase assays were carried out using the Dual-Luciferase Reporter (DLR) 
Assay System (Promega, USA), which contains Passive Lysis Buffer used to lyse 
the cells, as well as buffers and substrates for both the firefly and renilla 
luciferases. Firefly and renilla are two different enzymes acting on different 
substrates to produce a luminescent reaction. DLR enables the detection of the 
enzymatic activity of both enzymes within a single sample. 
Transfected cells were washed twice with cold PBS and then lysed with 










plate by using the plunger of a 1 ml syringe and the protein lysates were 
transferred into 1.5 ml centrifuge tubes, which were incubated at -70°C for a 
minimum of 30 minutes. 
Luciferase assays were performed according to the instructions of the 
manufacturer and luciferase activity was quantitated using a Luminoskan Ascent 
96 well plate luminometer. Briefly, the protein lysates were thawed at room 
temperature, vortexed and centrifuged (Z 233 MK-2, HEMLE) at 13 000 rpm for 
1 minute, and 10 μl of each sample loaded per well of a 96-well luminometer 
plate (DYNEX Microfluer 1). LAR II (50 µl), the substrate for firefly luciferase, 
was added to each well, the plate placed in the luminometer and the samples 
read and processed using the accompanying Ascent software. Firefly luciferase 
activity was stopped and renilla luciferase activity measured by adding 50 μl of 
Stop & Glo reagent to each well. Results obtained were normalized for 
transfection efficiency by dividing firefly readings by the renilla readings. The 
duplicate results were averaged and the fold activation calculated by dividing the 
readings obtained for the Mut-DAF by that obtained for the WT-DAF. 
 
2.3.6 Epstein-Barr Virus (EBV) transformation of B-lymphocytes  
(under supervision of Ms I Baumgarten; Chemical Pathology, UCT)  
Lymphoblastoid cell lines were established by transforming lymphocytes from 
peripheral blood of two MG patients and two healthy normal controls with the 
EBV as described below.  Peripheral blood was spun at 1000 x g to separate the 
buffy coat from blood plasma and red blood cells. To remove the remaining red 
blood cells and plasma from the buffy coat it was further treated with Ficoll-
hypaque, a high density liquid. The mixture was spun to allow the red blood cells 
to sink to the bottom and the plasma to move to the surface leaving the 
lymphocytes to form an interface layer between them. The lymphocytes were 
carefully taken from the interface, put into a new tube and washed twice with 
culture media (DMEM + 10% FCS + 1% P/S) and then incubated in 5 mls of 











The EBV culture media was prepared by culturing B95.8 cells, which serve 
as a source of EB virus, in a 75 cm2 flask and allowing the media of the cells to 
become acidic as judged by it turning yellow. The cells were not allowed to 
become over confluent so as to avoid cell death. The yellow media was then 
collected and put in a 50 ml conical tube, then spun down at 400 x g for 10 
minutes. The supernatant was removed and filtered through a 0.22 μm filter. The 
filtrate containing the EB virus particles without any donor cells was mixed with 
an equal amount of fresh medium, stored at 4°C for a maximum of 6 months and 
was used to transfect blood lymphocytes. 
To obtain only B-lymphocyte cell lines, lymphocytes obtained as described 
above were cultured in phytohaemagglutinin (PHA) (Welcome Reagents Ltd, 
UK), to get rid of T-lymphocytes, and EBV media in 25 cm2  flasks at 37ºC for 3 
days. Cells were checked twice a week and the media changed depending on 
the cell growth. 
 
2.3.7 Lipopolysaccharide (LPS) treatment of cells 
Cells were plated at 5 x 106 in 25 cm2 flasks containing DMEM and the next day 
the cells were treated with 10 μg/ml of LPS for six hours. The mRNA and protein 
were extracted from the treated cells and then analyzed by qRT-PCR or western 
blot analyses respectively. PBS was the vehicle used to dissolve LPS and 
therefore in all experiments, controls were included in which cells were treated 
with PBS instead of LPS. 
 
2.4 Western blot analysis 
2.4.1 Protein extraction 
Cells were cultured in 25 cm2 flasks in a total volume of 5 mls. Cells were spun 
down for 5 minutes at 400 x g and the medium removed. The cell pellets were 
washed twice with 1 ml of PBS and then spun in 1.5 ml microcentrifuge tubes for 
4 minutes at 12,000 rpm at 4ºC. Protein extraction was performed under non 












Table 2.4: Concentrations used to prepare the protein lysis buffer. 
 
 
The lysis buffer was supplemented with the appropriate protease inhibitors to 
maintain protein integrity. After the last washing step, cells were resuspended in 
lysis buffer and incubated on ice for 30 minutes and then centrifuged at 4ºC at 
12,000 rpm for 20 minutes to remove cell debris. The supernatant containing the 
cellular protein was stored at -70ºC. 
 
2.4.2 Protein quantification 
The total protein was quantified using the BCA Protein Assay Kit (Pierce, USA) 
which is based on the colour producing Biuret reaction of protein on Bicichoninic 
Acid (BCA) substrate. The intensity of the colour produced is nearly directly 
proportional to the amount of protein present. Nine standards of varying Bovine 
Serum Albumin (BSA) concentrations (0 to 2000 μg/ml), made up in the same 
buffer as the samples, were used to generate a standard curve. Briefly, a one-in-
six dilution of each protein sample was made up using 10 μl of sample and 50 μl 
of the lysis buffer. A total of 25 μl of the standards and the samples were loaded 
in duplicate in a 96-well plate. The BCA working reagent was prepared by 
combining 50 parts of BCA reagent A with 1 part of BCA reagent B (50:1, 
Reagent A: B) and 200 μl of this mixture was added to each protein sample. The 











performed using the Anthos 2001 spectrophotometer at 595 nm (Anthos Labtec 
Instruments) and the accompanying WinRead software V.2.3. The duplicate 
readings of the standards were averaged together and normalized to the blank 
standard and these were used to construct the standard curve. The standard 
curve was in turn used to obtain the concentrations of the protein samples. 
 
2.4.3 Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
The protein samples were separated on an 8% resolving gel (appendix A) with a 
5% stacking gel (appendix A). The gels were poured in the Biorad Mini Protein 3 
casting apparatus (Biorad, USA) according to the manufacturer’s instruction. 
Different plate sizes, 1.5 mm (thick) and 0.75 mm (thin) were used according to 
the total volume of protein to be loaded. The BRIC 216 antibody (IBGRL, UK) 
recognizes the DAF protein in its non-reduced form, therefore the preparation of 
the loading samples was done under non-reducing conditions i.e. SDS and 
Dithiothreitol (DTT) were not included in the loading dye (appendix A). The 
PeqGold Prestained Protein marker (PeqLab Biotechnologie, Germany) 
(appendix B) was loaded together with the samples for calibration purposes. 
Protein samples were loaded onto the SDS-PAGE and the gel placed into the 
electrophoresis tank apparatus filled with 1 x migration buffer (appendix A). 
Electrophoreses occurred at 100 Volts for approximately 90 minutes which gave 
a good separation of the proteins.  
 
2.4.4 Protein transfer 
Following separation of proteins on the gel, the protein was electrophoretically 
transferred onto a Hybond-ECL Nitrocellulose membrane (Amersham 
Biosciences, Germany), that was cut to the required size and trimmed at the left 
hand corner to identify the order in which samples were loaded. The membrane 
was carefully labeled with the date, amount of protein and the name of the cell 
lines used and then soaked in 1 x transfer buffer (appendix A). The gel and the 











(Schleicher & Schuell, Germany) in the following order: sponge/filter 
paper/gel/membrane/filter paper/sponge. All were securely clamped together 
and bubbles were avoided between the gel and the membrane. The whole 
assembling was performed in the transfer buffer to avoid the drying of the 
membrane. The sandwich was submerged in the transfer buffer and 
electrophoresis was applied at 100 Volts for 1 hour or 1 hour 30 minutes 
according to the thickness of the gel. 
   
2.4.5 Western blot detection 
After the transfer, the membrane was rinsed twice in 1 x PBS/0.1% Tween 
(appendix A) and then blocked in 5% milk in 1 x PBS/0.1% Tween for 1 hour at 
room temperature with a bit of shaking. The primary antibodies were diluted as 
follows: BRIC 216 DAF monoclonal antibody was diluted in milk at 1:100 
dilution, and the p38 rabbit polyclonal antibody (Cell Signaling Technology Inc., 
USA) was diluted in 1 x PBS/0.1% Tween at 1:5000 dilution. The membranes 
were incubated with the primary antibodies overnight at 4ºC and then washed 
with 1 x PBS/0.1% Tween two times 10 minutes and two times five minutes. 
After the washes the membranes were incubated for 1 hour at room temperature 
with gentle shaking with peroxidase conjugated anti-mouse and anti-rabbit 
secondary antibodies for DAF and p38 proteins, respectively. The blots were 
washed as before i.e. twice for 10 minutes and twice for five minutes before 
detection with the SuperSignal® West Pico Chemiluminescent Substrate kit 
(Pierce Biotechnology, USA). A total of 1 ml of the substrates A and B detection 
reagents (ratio 1:1) were added to a blot for 1 minute before the blot was 
sandwiched between acetate sheets in a cassette. The blot was exposed to X-
ray film for varying times and the film processed by immersing it in developer for 
five minutes, then washing in water and fixing for five minutes. The films were 














2.4.6 Stripping nitrocellulose membranes 
The membranes were immersed in pre-heated (at 55ºC) stripping buffer 
(appendix A) for 30 minutes, and then washed two times 10 minutes in 1 x 
PBS/0.1% Tween, after which standard western blots procedures followed. 
 
2.5 DAF mRNA expression analysis by quantitative real-time PCR (qRT-
PCR) 
Currently, qRT-PCR is the most precise method to measure and quantify mRNA 
levels. Quantitative RT-PCR is a PCR process in which an amplification product 
can be detected and measured simultaneously during each PCR cycle. This is 
achieved by using SYBR Green I, which is a fluorescent dye that is incorporated 
into the growing double stranded cDNA and emits a fluorescent signal on 
binding. The intensity of the fluorescence can then be correlated to the amount of 
PCR product. The reaction is characterized by a crossing point (CT), also known 
as the threshold cycle, which is the point where the target amplification is first 
detected. At this point the fluorescence intensity is greater than the background.  
The qRT-PCR reactions are carried out in glass capillaries that are placed 
in a thermocycler, Lightcycler machine (Roche, Germany), which controls the 
temperature required at each cycle of PCR, then exposed to excitation energy 
and the resulting fluorescence is measured by a photodetector. The cycling 
conditions are similar to those used in conventional PCR, however, in qRT-PCR 
there is inclusion of a melting curve step. This is an important step for reactions 
that make use of SYBR Green based kits, as SYBR Green can detect any 
double-stranded DNA including primer dimmers, contaminating DNA and PCR 
products of misannealed primer. Therefore, the melting curve analyses are 
carried out to ensure product specificity.  
 
2.5.1 RNA extraction from whole blood 
Quantification of messenger RNA (mRNA) levels in peripheral blood is 
complicated by the fact that mRNA is very unstable. It has been shown that 











individual mRNA species can change more than a 1000-fold during storage or 
transport at room temperature (Rainen et al., 2002). To avoid rapid degradation, 
the collection and handling of the blood samples should be carried out carefully. 
Several methods of blood collection have been employed that use anticoagulants 
like EDTA, heparin and citrate salts. These reagents prevent clotting but are 
unable to maintain the in-vivo gene transcript copy numbers. The collection of the 
whole blood in the above mentioned anticoagulants has been shown to be 
unstable over time (Rainen et al., 2002). For this reason we used the PAXgene™ 
Blood RNA System (PreAnalytiX, QIAGEN /BD Company, USA) that includes the 
PAXgene RNA collection tubes which have been shown to reduce RNA 
degradation in whole blood samples. The tubes contain a reagent that 
immediately stabilizes RNA by protecting its degradation by RNases and also by 
minimizing ex vivo changes in gene expression (Rainen et al., 2002).  
According to the manufacturer’s instructions, 10 ml of venous blood was 
collected into PAXgene tubes and kept at room temperature for 2 hours to allow 
for complete lysis of blood cells. The tubes were then stored at 4°C or -20°C, 
depending on the time lapse before RNA extraction. If RNA was to be extracted 
from the blood within 5 days then blood was stored at 4°C but if RNA extraction 
was to be done within 2 weeks to 6 months, blood was stored at -20°C. Total 
RNA was extracted from whole blood using the PAXgene Blood RNA kit. Briefly, 
the nucleic acids were pelleted by centrifuging the lysed blood in the PAXgene 
tubes. Proteins were digested by addition of optimized buffers together with 
proteinase K. RNA-containing lysate was filtered through a PAXgene Shredder 
spin column and ethanol added to allow selective binding of RNA in the filtrate 
while spinning contaminants through the PAXgene RNA spin column. DNase I 
was included in subsequent washes to remove the traces of bound DNA. The 
purified RNA was finally eluted in elution buffer and heat denatured.  
 
2.5.2 RNA extraction from lymphoblastoid cell lines 
Total RNA extraction from Epstein-Barr virus (EBV) transformed lymphoblastoid 











USA). Diethyl pyrocarbonate (DEPC) treated microfuge tubes and pipette tips 
(Appendix A) were used to minimize RNA degradation during the extraction 
process as DEPC destroys RNases. Cells were harvested by centrifugation and 
then homogenized in a denaturing guanidine-isothiocyanate-containing buffer. 
Effective removal of genomic DNA (gDNA) is facilitated by passing the 
homogenate through a specially designed genomic DNA Eliminator spin column. 
This is important as the presence of gDNA can result in false positives if 
amplified during the reverse transcription step. The RNA in the flow-though was 
allowed to bind to the membrane of the RNeasy spin column by addition of 
ethanol prior to centrifugation. Purified RNA could then be obtained by elution 
with RNase free water. 
 
2.5.3 Measuring RNA concentration and integrity  
The concentration and purity of purified RNA was determined using the 
NanoDrop as described for DNA in section 2.1.3. RNA integrity was additionally 
assessed by electrophoresis on a 1% agarose gel and observing the separation 
between 28S and 18S bands by visual assessment under the UV 
transilluminator. This is important because the success of the reverse 
transcription process depends on the integrity and purity of the starting RNA  
 
2.5.4 Reverse transcription 
RNA is very easily degraded by RNases that are always present in the 
environment; therefore, the RNA is usually converted to complimentary DNA 
(cDNA), which is more stable and more convenient to work with. cDNA is a 
double-stranded DNA synthesized from RNA during the reverse transcription 
process using the reverse transcriptase (RT) enzyme. mRNA was transcribed 
into cDNA by using the Improm-II Reverse Transcription System (Promega, USA) 
following the manufacturer’s instructions. All microfuge tubes and pipette tips 
were DEPC treated before use. Briefly, either 500 ng or 1 μg of RNA was 
combined with 1 μl of Oligo (dT)15 primer in a total volume of 5 μl, and then heat 











The mixture was incubated for 5 minutes at 25°C in a controlled-temperature 
heating block for the annealing process to take place and the cDNA strands 
allowed to extend at 42°C for an hour. The Reverse Transcriptase was then 
inactivated at 70°C for 15 minutes and the cDNA stored at -20°C. A negative 
(No-Template) control was prepared by replacing RNA template with nuclease 
free water. It was deemed unnecessary to include a negative (no RT) control in 
which no reverse transcriptase was added, as the PCR primers were designed to 
eliminate the possibility of amplifying genomic DNA and DNase I was included in 
the RNA extraction process. 
 




2.5.5 Quantitative Real-time PCR (qRT-PCR) 
The Sensimix Lite kit (Quantace, UK) was used to quantify the mRNA expression 
levels of the target gene gDAF and the house-keeping genes GUS and GAPDH 
following the manufacturer’s instructions. Briefly, reagents were mixed in glass 
capillaries to a final volume of 10 or 20 μl as shown in Table 2.6. The procedure 
was performed in the Lightcycler machine and the levels of fluorescence were 
quantified using the accompanying Light Cyler Software Version 3 (Roche, 











keeping genes but differed in the holding times in the cycling step as shown in 
Tables 2.7 and 2.8. Similarly to conventional PCR, the several parameters 
altered to achieve optimal conditions. After the amplification process, the PCR 
products were run on a 3% agarose gel to ensure that the right sized products 
were obtained. 
 
Table 2.6: Summary of optimized real time PCR parameters used for 































2.5.6 Quantification of mRNA and establishing the standard curves 
There are two types of RT-PCR quantification, absolute quantification and 
relative quantification. The absolute quantification allows the expression level of 
the target gene to be given as an absolute copy number. Absolute quantification 
employs a standard curve that is generated by the use of serially diluted 
standards of known concentrations. Relative quantification is when the level of 
gene expression is calculated by a comparative crossing point method in which 











the sample and the control. House-keeping genes are genes that are usually 
expressed to effect basal cellular function and are used as endogenous 
reference genes whose expression level should not differ from sample to sample 
or between patients and controls (Eisenberg and Levanon, 2003). The house-
keeping gene is used as a reference and can indicate variability in the processes 
leading to qRT-PCR, such as RNA extraction process and reverse transcription 
process. 
The amplification efficiencies for the target gene and the house-keeping 
gene should be comparable for one to carry out relative quantification using the 
comparative method. If the efficiencies of the two genes are not comparable, an 
external standard has to be employed (Giulietti et al., 2001). Amplification 
efficiency is the rate at which the PCR products are increasing exponentially. The 
efficiency of RT-PCR is shown by the value of the slope of the standard curve. A 
reaction is said to be 100% efficient when it has a slope of -3.322 and any value 
less than this is an indication that the PCR is less than 100% efficient. If the 
amplification efficiencies of the target gene and the house-keeping gene are not 
equal, the quantity of each sample is first calculated using the standard curve 
and then it is expressed as a ratio of the amount of the house-keeping gene 
concentration calculated from the standard curve.  
To construct a standard curve, serial dilutions from the cDNA of a normal 
healthy control (BN) sample were prepared according to the given protocol (see 
Appendix C). The cDNA was amplified in excess for each set of primers, Gspec 
(for gDAF gene), GUS and GAPDH, by setting up five PCR reactions of 20 μl 
each on the Lightcycler machine and a small volume of the PCR product run on a 
2% agarose gel to check that the PCR product was of the right size. The 
amplification reactions were then transferred from the lightcycler capillaries into 
microfuge tubes and cleaned up using the Wizard SV Gel and PCR Clean-up 
System (Promega, USA) as per manufacturer’s instruction. The concentration 
and the integrity of the purified PCR product was measured using the NanoDrop 











A dilution series from 107 down to 103 was prepared for gDAF, GUS and GAPDH 
purified PCR products, in order to be able to construct a standard curve for each 
gene. RT-PCR was performed in triplicate for all the dilutions and standard 
curves were constructed on the Roche Lightcycler by plotting the CT values on 
the y-axis against the log of the initial template concentration. There is a linear 
relationship between the CT and the initial amount of the total RNA or cDNA, and 
this allows for the calculation of the concentration of the unknown samples. The 
standard curve was only constructed once for each gene. Therefore it is 
important to include one of the standard curve serial dilutions in each subsequent 
run in order to normalize against the standard curve to correct for inter-assay 
variability. The qRT-PCR data was analyzed by relative quantification, using both 
the standard curve and the 2-ΔΔCt methods (presented by PE Applied Biosystems, 
Perkin Elmer, CA).  
 
2.6 Transcription factor binding site (TFBS) analysis 
We performed a direct matching of the known TFBSs contained in the 
TRANSFAC Professional database v.11.2. (Matys et al., 2006). This has been 
done with the Patch™ program of the Transfac suite (Matys et al., 2006).  We 
used matching of motifs with length of 7 bp and with no mismatch between the 
template motif and the matched sequence.  We considered that the motif is 
affected by the SNP if it includes the SNP nucleotide. Our results indicate that a 
Sp1 binding site in genomic sequence (C nucleotide version) has been lost when 
G nucleotide replaced C nucleotide.  The new putative TFBS obtained was that 

















CHAPTER 3: RESULTS 
All patients used in this study had been diagnosed with MG by Prof Heckmann as 
described (Heckmann et al., 2007), and had attended more than two follow up 
visits at the University of Cape Town Myasthenia clinic, located at Groote Schuur 
Hospital. In a previous study, Heckmann et al., 2007 observed that more MG 
patients of African ancestry (Blacks and M/A) were developing a treatment-
resistant severe extra-ocular muscle (EOM) MG phenotype compared to the 
White patients. The EOMs have been shown to express less complement 
regulatory proteins (CRPs) than other tissues (Kaminski et al., 2004; Conti-Fine 
et al., 2006) and are thus more susceptible to diseases associated with 
complement damage such as MG. Of the known CRPs, DAF has been shown to 
provide the substantial protection for the eye tissues (Lass et al., 1990) from 
complement injury. A lack of DAF has also been shown to increase susceptibility 
to complement injury in mice as described in the introduction (Lin et al., 2002).  
 
3.1 Two SNPs were found in the 5` upstream region of the DAF gene 
To determine whether the severe EOM MG phenotype is due to reduced DAF 
expression, the first aim of this study was to screen for base changes in the 5` 
upstream regulatory and selected coding regions of the DAF gene. The minimal 
promoter region of the DAF gene was PCR-amplified from DNA obtained from 
136 MG individuals and 167 healthy racially matched controls. The PCR primers 
were designed for the amplification of approximately 500 bp upstream of the ATG 
start codon of the DAF gene. Agarose gel electrophoresis of PCR products 
revealed a band of the expected size (Figure 3.1) for each sample tested and no 
band was observed in the negative (no template) control. The absence of non-
specific bands in the lanes rendered the PCR sample suitable for direct 












Figure 3.1: Bands of approximately 500 bp of the DAF promoter were PCR-
amplified as shown by the photograph of a 2% agarose gel. Lane 1-6 = DNA 
samples; 7 = water blank; 8 = Molecular Weight marker (GelPilot 100 bp Plus 
Ladder). 
  Sequencing was generally performed in one direction using the sense 
primer and where necessary in both directions. The PCR products were cycle 
sequenced and then ethanol precipitated before they were electrophoresed and 
analyzed on the ABI Prism 3100 system. The analysis program provides 
electropherograms showing peaks of different colours for the four bases (Figure 
3.2 and 3.3). Whenever the program reads a peak as N it is because of the 
uncertainty of the base at that position. Insertions, deletions or base changes 
within the sequence were easily detected by comparing to the consensus DAF 
sequence as obtained from Genebank RefSeq-file NM_000574. These changes 
may cause a shift in one strand in relation to the other in the electropherogram 
making it difficult to read beyond the base change. Two SNPs were found to be 
of interest to this study with regard to MG. These were the c.-244_-243insA, an 
adenine insert between nucleotides -244 and -243, and the c.-198C>G, a 
cytosine to guanine change at position -198 from the transcription start site.  
The electropherograms for (A) the normal sequence with CC alleles, (B) 
the heterozygotes with CG alleles, and (C) the GG homozygous sequence are 
shown in Figure 3.3. A single peak (shown by the arrow in Figure 3.3A and C) 
shows that both alleles of the gene have the same base at that point, indicating 
homozygosity. In the case of heterozygosity (Figure 3.3B), two peaks of similar 
heights which are superimposed on each other and have reduced height 











Figure 3.2: Sequencing electropherograms showing the position where the c.-
244_-243insA occurred. Diagram A) shows the normal sequence with no insert. 
B) shows the sequence with a homozygous A insert and C) shows a sequence 
with a heterozygous A insert and the subsequent shift of one strand to another.  
 
Figure 3.3: Sequencing electropherograms of part of the DAF promoter region 
showing A) normal sequence and B) the c.-198C>G heterozygous SNP indicated 












3.2 The c.-198C>G SNP is more prevalent in the African genetic ancestry 
individuals and is more associated with the severe EOM MG 
phenotype.  
The c.-244_-243insA was observed in 28 out of 136 of the MG patients and 50 
out of 167. Of these changes, six patients and nine controls were homozygous 
and 22 patients and 41 controls were heterozygous for the variant (Table 3.1).  In 
all of the heterozygotes the reading sequence beyond the SNP insertion point 
became unreadable and the PCR products had to be sequenced in the reverse 
direction to check for sequence changes in the region beyond the A insert 
(Figure 3.2C). No additional changes to the sequence of the minimal promoter 
were observed in individuals carrying the A insert. The c.-244_-243insA was 
observed to be more prevalent in the controls of African-ancestry (Black and 
M/A) (49 of 132) compared to the White controls (1 of 35) (Table 3.1). A similar 
trend was observed among the MG patients with 27 of 103 of those of African 
genetic ancestry with the A insert compared to only 1 of 34 of the White MG 
patients. The c.-244_-243insA SNP allele frequencies did not appear to differ 


















Table 3.1: Comparison of c.-244_-243insA allelic frequency and (%) within the 
MG patients and controls 
 
Overall, the c.-198C>G SNP was identified in eight out of 136 MG patients and 
six out of 167 controls (Table 3.2). There was only one homozygote for the 
variant and the remaining patients were all heterozygous. All of the c.-198C>G 
SNPs were detected in individuals of African ancestry (Black and M/A) and was 
absent in both the White MG patients and controls. No additional base changes 




















Table 3.2: Comparison of the allelic frequency in individuals (%) with the c.-
198C>G in the MG patients and controls 
 
The allelic frequencies and odds ratio of the c.-198C>G in association with the 
EOM phenotype are shown in (Table 3.3). Overall, the c.-198C>G SNP did not 
show significant association with the MG patients, but was found to be 
significantly more associated with the African ancestry MG patients having the 
severe EOM phenotype (p = 0.009). The MG subjects belonging to the Black 
subpopulation were more likely to develop paresis of at least one EOM if they 
have the c.-198C>G promoter SNP as shown by the odds ratio of 12.9 (p = 
0.006). The Black MG patients with the c.-198C>G SNP also had increased 
likelihood of developing pareses of at least 5 EOMs (p <0.01). Similarly, in the 
M/A patients the SNP was significantly associated with the developing of one or 
more EOM dysfunction (p = 0.022) but not with the developing five or more EOM 
paresis (p-value = 0.27). However, when the findings for the patients of African 
genetic-ancestry (Black and M/A) were combined, the likelihood of developing 
EOM with at least five or more dysfunctions was significantly increased in the 














Table 3.3: Association of the c.-198C>G SNP with treatment-resistant EOM 
involvement in South African MG subpopulation 
 
EOM= Extraocular muscle; EOM-N= normal eye movement; EOM≥1 = a least 
one of the 12 EOM’s is dysfunctional; EOM≥5 = a least 5 out of 12 dysfunctional 
EOM’s; C = racially matched controls; **ss32475790; # One individual with 
thyroid eye disease excluded from the analysis; Odds ratios were calculated 
relative to the normal controls; The exact p-values are 2-tailed; 95% CI = 95% 













The DNA samples from 50 MG individuals were screened for base changes in 
exons 3, 4 and 5 which encode critical components of the classical complement 
pathway. No genetic variants were observed in these three exons or in their 
intron-exon splice junctions and for this reason comparative studies with normal 
healthy controls were not deemed necessary. Eleven MG patients representing a 
spectrum of clinical phenotypes were screened for mutations in the region of 
exons 7, 8, 9 and 14 which encode for the GPI membrane anchorage for the DAF 
gene. Similarly, no sequence variations were observed in these exons. 
 
3.3 The c.-198C>G affects basal DAF promoter activity  
Once it was established that the c.-198C>G was significantly associated with the 
severe EOM MG phenotype, we investigated its effect on the DAF promoter 
activity using site directed mutagenesis and luciferase reporter assays. The 
guanine residue at position -198 within the DAF promoter, already cloned into a 
pGL3 luciferase vector, was mutated to cytosine by site-directed mutagenesis 
(generated by Dr H. Teng) and is referred to as Mut-DAF promoter throughout 
this thesis. 
To determine the suitable amount of plasmid DNA to use for transient 
transfections, various concentrations (450 ng, 900 ng and 1800 ng) of the firefly 
reporter driven by either the wild type WT- or Mut-DAF promoter constructs were 
transfected into the HT 1080 cells and luciferase activity was measured. This cell 
line was used due to its ability to easily take up foreign DNA. The TK-renilla 
construct was included in all experiments as an internal control for measuring 
transfection efficiency. The results of one transfection experiment, which is 
representative of two independent experiments performed each time in duplicate, 
are shown in Figure 3.4. While very little difference in luciferase activity was 
observed between the WT- and the Mut-DAF promoter activity in the cells 
transfected with 450 ng and 900 ng of DNA, cells transfected with 1800 ng of 











than the WT-DAF promoter. Based on these results, 1800 ng of DNA was used in 
all future transfection experiments. 
 
 
Figure 3.4: Dose curve to determine the amount of plasmid DNA to be used in 
transient transfections. HT 1080 cells were transfected with 450 ng, 900 ng or 
1800 ng of either the WT- and Mut-DAF promoter reporter constructs. After a 30 
hour transfection period, cells were lysed and data was normalized against TK 
Renilla to determine promoter activity (A). A significant difference between WT- 
and Mut-DAF promoters was observed using 1800 ng of DNA as shown by the 
fold activation graph in (B). The results shown are representative of two 
independent experiments performed in duplicate. 
 
To confirm that the effect of the c.-198C>G SNP on DAF promoter activity 
observed above was not  cell type dependent, COS-7 cells were included in the 











1800 ng of either WT- or Mut-DAF. Figure 3.5 A and C show that the relative 
luciferase activities in both cell lines were higher in the cells transfected with the 
Mut-DAF compared to the WT-DAF. On average, a 2-fold increase in the Mut-
DAF promoter activity was observed in comparison to the WT-DAF in both cell 
lines (Figure 3.5 B and D). These results confirmed that the c.-198C>G SNP 
resulted in an increase in DAF promoter activity and that this effect was 
independent of the cell type used. 
  
Figure 3.5: Effect of c.-198 C>G SNP on DAF promoter in COS 7 (A and B) and 
HT1080 (C and D) cells. The cells were transfected at approximately 80% 
confluency with 1800 ng of WT- or Mut-DAF promoter constructs. TK-Renilla 
luciferase was used as an internal control for transfection efficiency. The cells 
were lysed after 30 hours of transfection and luciferase activity measured. The 
results were normalized against the TK-Renilla activity and the relative luciferase 
activity represented in bar graphs A (COS 7 cells) and C (HT1080 cells). B and D 
show the ~ 2-fold increased activation observed in the cells transfected with the 
Mut- compared to the WT-DAF of COS 7 and HT1080 cells, respectively. The 
results shown are representative of 3 independent experiments that were 











The next experiment was conducted  to determine whether the effect of the c.-
198C>G SNP seen above could be repeated in muscle cells, which is more 
representative of the tissue involved in MG patients. This was investigated by 
transiently transfecting the undifferentiated muscle cell line C2C12 as above with 
1800 ng of either the WT- or Mut-DAF. In these experiments, some C2C12 cell 
plates were harvested after 30 hours of transfection and other cell plates were 
allowed to differentiate by changing the growth medium to differentiation medium 
supplemented with 2% Horse serum and left for another 48 hours. These will 
henceforth be referred to as undifferentiated and 48-hour differentiated C2C12 
cells, respectively. Figure 3.6 shows that after 48 hours in differentiation medium 
the spindle-shaped cells had started to fuse and become more elongated to form 
thin muscle fibres. The results of one transfection experiment, which is 
representative of three independent experiments done each time in duplicate, are 
shown in Figure 3.7. As can be seen, the c.-198C>G SNP led to an 
approximately 2-fold increase in the activity of the Mut-DAF promoter in both 
undifferentiated and 48-hour differentiated C2C12 cells thus confirming the 
results shown in Figure 3.5. Cells in some plates were left in differentiation 
medium for a period up to 10 days to determine the effect of the c.-198C>G SNP 
on promoter activity during prolonged differentiation period. The cells were lysed 
and luciferase activity determined. Three independent experiments were 
performed each time in duplicate. Unfortunately, the results showed negligible 
renilla luciferase activity indicating poor transfection efficiency and there was no 
















Figure 3.6: 48-hour differentiated C2C12 cells. C2C12 cells were allowed to 
differentiate by changing the growth medium (DMEM + 10% FCS + 1% P/S) to 
differentiation medium (DMEM + 2% Horse Serum + 1% P/S) and incubating 
them at 37ºC for 48 hours. After 48 hours the spindle-shaped myoblast-like cells 

















Figure 3.7: Luciferase activity in C2C12 (Mouse myoblasts) cells. Cells were 
transfected with 1800 ng of either the WT- or the Mut-DAF constructs and 
harvested after 30 hours of transfection. For differentiation, the growth medium 
was substituted with differentiation medium containing 2% Horse serum and 
allowed to differentiate for 48 hours. Cells were lysed and the data normalized to 
TK renilla to obtain luciferase activity (A). There was ~ a 2-fold increase in the 
Mut-DAF compared to the WT-DAF in both the undifferentiated and the 48-hour 
differentiated C2C12 cells (B). The results shown are representative of 3 
independent experiments that were performed in duplicate. The error bars 











3.4 The c.-198C>G does not appear to have any effect on endogenous DAF 
mRNA expression levels in the human lymphocytes 
Having shown that the c.-198C>G led to increased promoter activity in the Mut-
DAF, the effect of the c.-198C>G SNP on DAF mRNA levels in MG patients was 
next investigated. Total RNA was extracted from blood lymphocytes contributed 
by eleven MG patients attending the MG clinic. These patients had varying 
clinical characteristics as shown in Table 3.4. 
Table 3.4: The clinical characteristics of the MG patients used for peripheral 
blood lymphocyte DAF mRNA expression 
 
* Patient 4 had severe generalised refractory MG without ocular involvement.  
Whole blood was also collected from 6 controls for RNA extraction. The 
extracted RNA was reverse transcribed into cDNA and DAF mRNA was 
quantified using quantitative real-time PCR (qRT-PCR) with primers specific to 
the gDAF isoform. DAF relative expression levels were normalized against the 











Figure 3.8 shows the result of a typical qRT-PCR experiment. During the PCR 
amplification, the accumulation of fluorescent emission at each reaction cycle is 
plotted on the PCR amplification curve for each sample. The amplification curve 
can be divided into three main phases, the linear ground phase, the exponential 
phase and the plateau phase (as outlined in Critical factors for successful Real-
time PCR handbook). The linear ground phase is a reflection of no detectable 
increase in fluorescence due to amplification products. As the reaction moves 
into the exponential phase, there is an increase in the product and finally the 
reaction enters the plateau phase where no additional product is detected. 
Figure 3.8B shows the melting curves for these reactions showing a single peak 
at a temperature of about 85ºC. The single peak indicates the presence of a 
single product and the absence of primer-dimer contamination. Aliquots of the 
qRT-PCR reactions were run on 2% agarose gels to confirm that the peak on the 
melting curve was generated from a PCR product of the expected size (Figure 
3.9). The correct product sizes were: gDAF (322 bp), GAPDH (119 bp) and GUS 





















Figure 3.8: A) Amplification curves of DAF mRNA from the peripheral blood 
lymphocytes of the MG patients and normal controls. The cycle numbers are 
plotted on the x-axis, while the fluorescence is plotted on the y-axis. Initially, 
between cycles 1 and 17, there is no detectable amount of amplification product. 
This section is then followed by the exponential phase in which the product is 
detected, between cycles 18 and 26. The last phase is the plateau phase which 
shows that there was no significant increase in PCR product taking place (cycles 
27 to 35). The experiments were performed three times and each sample was 
performed in duplicates. B) For the melting curve, temperature is plotted against 
the change in fluorescence with time. A single peak shows that a specific product 
was generated, and the absence of peaks at other temperatures shows that there 















   
 
Figure 3.9: 2% agarose gel picture. 5 µl of the qRT-PCR products were run on 
2% agarose gels and visualized under UV light using SYBR gold (1:2000) 
fluorescent dye. MW = 500 bp molecular weight marker. Lane 2 and 3 are gDAF 
products of approximately 322 bp. Lane 5 and 6 are GAPDH products of 
approximately 119 bp. Lane 8 and 9 are GUS B products of approximately 96 bp. 
Lane 4, 7 and 10 are water blanks for each gene amplified. Absence of a band in 












Standard curves were generated for each gene by carrying out qRT-PCR on 
serially diluted cDNA samples of known concentrations as mentioned in section 
2.5.6. The resulting standard curves produced a linear relationship between the 
CT values and the initial amount of total cDNA. Using the LightCycler machine 
version 4.1 software, the standard curves were constructed and the slope of the 
curve used to calculate the PCR efficiency. The resulting standard curves had 
efficiencies above 80% (gDAF 88.4%; GUS B 86.9%; and GAPDH 82.2%). The 
standard curve for each gene was constructed only once and used for all 
subsequent runs. Thus, for each consecutive qRT-PCR run one standard curve 
dilution sample was included in order to correct for inter-run variability. Absolute 
concentrations of samples in the current run could thus be read from the 
standard curve generated previously.  
 Gene expression was determined using the standard curve and the 
comparative 2-ddCT methods (Wong and Medrano, 2005) of relative quantification. 
Both methods produced similar results, which were further represented in a box-
and-whisker plot in Figure 3.11. The DAF mRNA expression levels in both 
patients and controls showed no difference in the distribution trends and no 
significant differences were observed (p-value > 0.05). Both sets of data were 
shown to follow a normal distribution by the Shapiro-Wilk test. 
 
Figure 3.10: The box-and-whisker plot showing the distribution of data of the 












3.5 The c.-198C>G increases endogenous DAF mRNA level  in 
lymphoblastoid cell lines 
As all MG patients were on at least one or more immunosuppressive drugs at the 
time of blood sampling, it was possible that variation in DAF expression between 
MG patients and controls was masked by the effect of the drugs on DAF. It was 
therefore necessary to repeat the experiment in an environment in which the 
effect of the drugs would be absent. This was achieved by generating 
lymphoblastoid cell lines using Epstein - Barr virus (EBV) transformation in an 
environment devoid of the MG drugs. The cell lines were transformed from the 
whole blood of four MG patients (Table 3.4), three of whom had the c-198C>G 
SNP and one patient who did not (WT/MG). Additionally, one further MG patient 
with the SNP who was not included in the previous experiment and two normal 
healthy controls without the SNP (WT) were also included. RNA from the cell 
lines was reverse transcribed into cDNA and DAF mRNA levels quantified by 
qRT-PCR. The results, which are representative of two independent experiments 
performed each time in duplicate, are shown in Figure 3.12. DAF mRNA levels 
were upregulated, relative to the housekeeping gene, in three MG cells lines with 
the c.-198C>G SNP, with only one MG4 cell line showing reduced activity. 
However, the MG cell line without the SNP (WT/MG) also showed increased 
relative DAF expression compared to the WT cell lines (Figure 3.12). The 
findings in the three MG cell lines support the luciferase promoter activity 
experiments performed in the COS 7, HT1080 and C2C12 cells which showed an 
upregulation of the promoter as a result of the c.-198C>G SNP (section 3.2). The 
upregulated activity in the WT/MG may be attributed to some other factor which 
















Figure 3.11: DAF expression in EBV transformed lymphoblastoid cell lines. 
Relative fold expression was normalized to the house-keeping gene GUS. The 
fold change was usually higher in the patient cell lines with or without the c.-
198C>G (WT/MG, MG1, MG2 and MG3) than in the control cell lines (WT1 and 
WT2). The MG4 cell line was the odd one out with DAF mRNA expression being 


















3.6 There is a possible loss of a putative Sp1 transcription factor as a result 
of  the c.-198C>G SNP 
Once it was established that the c.-198C>G SNP generally appears to upregulate 
the expression and the basal promoter activity of the Mut-DAF, the next step was 
to predict whether the c.-198C>G change causes a loss or gain of putative 
transcription factor binding sites. This was achieved by searching the Consite 
database (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/) for possible 
transcription factor binding sites in the 5` flanking region of the DAF gene. Five 
Sp1 (Sp1-A to Sp1-E) binding sites were identified within 248 base pairs 
upstream of the ATG start codon of the WT-DAF sequence, one of which (Sp1-B) 
was lost when the c.-198C>G SNP was present (Figure 3.13). Furthermore, 
bioinformatic interrogations were done on the DAF promoter SNP sequence 
using the TRANSFAC Professional database v.11.2 (as reported in Heckmann et 
al. 2009) which confirmed the loss of a putative Sp1 transcription factor binding 
site (performed by Prof VB Bajic and Dr M Kaur from the SANBI Bioinformatics 
unit). 
We next investigated the functional significance of losing the Sp1-B 
binding site by transiently co-transfecting the HT1080 cells with 150 ng of pCMV-
Sp1 (a Sp1 expression plasmid) and 800 ng of WT- or Mut-DAF. Basal levels of 
firefly luciferase activity were measured by co-transfecting the WT- or the Mut-
DAF constructs with an empty control vector (pCMV). The Sp1 expression 
plasmid seems to have a similar effect on both the WT- and the Mut-DAF 












Figure 3.12: Nucleotide sequences of part of the DAF promoter region showing a 
total of 248 nucleotides from the initiation ATG start codon in the human DAF 
gene. The boxes show the sequences corresponding to the consensus binding 
site of Sp1 transcription factor. Multiple transcription start sites are shown by the 
arrows (Thomas and Lublin, 1993) and the main transcription start site is shown 
by the bent arrow (Ewulonu et al., 1991) A) Shows the WT-DAF promoter 
sequence with 5 Sp1 binding sites upstream of the ATG start codon and B) 
shows the Mut-DAF (with the c.-198C>G SNP) which has lost one Sp1 (Sp1-B) 













Figure 3.13: Effect of Sp1 transcription factor on the WT-DAF and the Mut-DAF. 
The WT- and Mut-DAF were co-transfected with the Sp1 construct or the empty 
(pCMV) vector into HT1080 cells. The Sp1 transcription factor had the same 
effect on the DAF promoter with or without the c.-198C>G SNP.  
 
Previously, it was reported by Cauvi et al. (2006) that the two Sp1 binding 
sites most proximal to the transcription start site are the key Sp1 binding sites 
involved in the basal transcription of the mouse Daf1 gene, whereas the third Sp1 
binding site 5` of the transcription start site did not have any effect on the Daf1 
promoter activity (see discussion later). In our study the lost Sp1-B binding site is 
the third from the transcription start site. Although we have shown that the c.-
198C>G SNP does have an effect on DAF promoter activity, the results from 
Figure 3.14 show that Sp1 does not appear to have a differential effect on either 
















3.7 The DAF regulatory region c.-198C>G SNP influences the 
lipopolysaccharide (LPS-) induced DAF upregulation 
Thus far we have shown that the c.-198C>G SNP is functional but we have not 
been able to explain the association of the observed increased basal DAF 
promoter activity with the loss of the putative Sp1 site. A number of studies have 
previously shown that LPS, which has the ability to initiate an inflammatory 
response, upregulates DAF mRNA expression levels (Iborra et al., 2003). 
Furthermore the LPS effect on Daf1 gene expression was abolished by deletion 
of the Sp1 binding sites most proximal to the transcription start site (Cauvi et al., 
2006). We next investigated the effect of LPS on DAF mRNA expression levels in 
the presence and absence of the SNP. To achieve this, the lymphoblastoid cell 
lines from section 3.5 were cultured with 10 µg/ml of LPS or 1x PBS (vehicle) for 
6 hours and mRNA levels measured by qRT-PCR with or without LPS treatment.  
In the control cell lines treated with LPS, our results showed the expected 
upregulation of the DAF mRNA expression levels. Similarly, there was increased 
mRNA expression in the MG patient cell line without the c.-198C>G SNP 
(WT/MG). However, there was a reduction in DAF mRNA expression levels in all 
the LPS treated in all the MG-SNP cell lines (Figure 3.15 A). These experiments 
were performed at least twice in duplicate. 
Within a cell, an increase in transcription of a gene does not necessarily 
result in an increase in its protein levels. Thus, it was important to assess DAF 
protein levels to be sure that the reduced DAF mRNA transcription also results in 
reduced protein levels. We treated two lymphoblastoid cell lines, one WT and 
one MG1, with 10 µg/ml of LPS or 1x PBS for 6 hours as before. The protein was 
extracted under non-reducing conditions and then subjected to western blot 
analyses with a DAF specific antibody. All blots were re-probed with the p38 
specific antibody as a loading control (Figure 3.15B). The results were confirmed 
by densitometry readings of the western blot autographs and the readings are 











2.4 fold increase and ~ 2.4 fold decrease in the protein levels of the WT and the 
MG1 cell lines, respectively. The WT cell line therefore showed a significant 
increase in protein level in response to LPS treatment whereas the protein levels 
were decreased in the MG cell line. These results thus supported the DAF mRNA 
expression levels observed in this study. 
 
 
Figure 3.14: LPS treatment did not upregulate DAF expression in the SNP-
lymphoblastoid cell lines. A) Bar graph shows the qRT-PCR results that illustrates 
the increased mRNA levels in the control cell lines (WT1 and WT2) and the patient 
cell line without the SNP (WT/MG), and the reduction in the patients with the SNP 
cell lines (MG1-4) in response to LPS-treatment. B) Western blot analysis done on 
the LPS-treated control and patient cell lines showed an increase in the protein 
levels of the LPS-treated control cell line (WT1) and a reduction in the protein 
levels of the SNP cell line (MG1). p38 was used as a loading control. The bar 
graph shows densitometry readings from the autoradiograph of DAF protein levels 
normalized to p38 protein levels. For the control cell line, DAF protein levels 
showed an increase of ~2.4 folds as a result of LPS treatment. In contrast, the MG 


















3.8 Brief summary of the results 
In conclusion, I have shown that the c.-198C>G SNP is associated with a severe 
EOM phenotype in MG patients, and that the SNP has an effect on basal 
expression of the DAF gene. I have also identified that there may be loss of a Sp1 
transcription binding site in the region where the c.-198C>G SNP occurs and that 










CHAPTER 4: DISCUSSION 
Myasthenia gravis is an autoimmune disorder caused by abnormally activated 
complement producing auto-antibodies against the acetylcholine receptors 
(AChRs) resulting in damage at the NMJ. The classical complement pathway is 
controlled, in part, by regulatory proteins such as DAF which accelerate the 
decay of the C3 and C5 convertase complexes. Several studies in humans and 
mice have shown that a deficiency of DAF can result in inflammatory disorders, 
autoimmune disease development and susceptibility to experimental 
autoimmune MG (Lublin et al., 1994; Miwa and Song, 2001; Lin et al., 2004; 
Kaminski et al., 2006). The involvement of EOM in MG is a trademark of the 
condition in humans (Ubogu and Kaminski, 2001). In the EOMs of rats and mice, 
DAF expression is known to be generally lower than in other skeletal muscles 
(Porter et al., 2001) which may also be a feature of human EOM. Thus we 
reasoned that the MG patients developing a severe EOM phenotype may have 
lower background or inducible DAF expression which can lead to increased 
susceptibility of the EOM to complement injury. This study therefore represents 
the first supportive evidence for DAF’s involvement in human MG pathogenesis.  
A c.-198C>G SNP was detected in the 5` upstream regulatory region of 
the DAF gene and was found to be significantly associated with a severe EOM 
phenotype in MG individuals of African ancestry (p= 0.0003). This SNP was 
shown to alter the DAF promoter activity in three different cell lines. Transient 
transfections with Mut-DAF (having the c.-198C>G SNP) yielded approximately a 
2-fold increase in the basal DAF promoter activity compared to WT-DAF in COS 
7, HT 1080 and C2C12 cells. In addition, increased basal DAF mRNA expression 
was observed in three human lymphoblastoid cell lines with the SNP compared 
to two WT controls. The SNP was also found to alter the number of transcription 
factor binding sites (TFBSs) in the DAF 5` regulatory region. Direct matching of 
known TFBSs to the flanking region of the SNP showed that there is a possible 
loss of a putative Sp1 binding site (Heckmann et al., 2009). Co-transfection of 
WT- and Mut-DAF with Sp1 expression vectors showed that the loss of the Sp1 











loss of this Sp1 site was shown to down-regulate LPS-induced DAF mRNA 
expression. The findings of this study indicate that the c.-198C>G SNP 
influences DAF regulation, specifically the body’s ability to upregulate DAF 
expression in response to bacterial products such as LPS, which may aggravate 
the progression of human myasthenic disease.   
 
4.1 A c.-198C>G SNP associates with the severe EOM phenotype in MG 
Numerous studies have shown that a single base change, also known as a SNP, 
in the coding region of genes may lead to a change in the amino acid sequence 
of the translated protein (Knight, 2003).  The DAF protein CCPs 2 and 3 are 
important in the control of the classical complement pathway (Coyne et al., 1992) 
and mutations occurring in these regions disrupt the function of the CCPs in the 
regulation of complement activation. Deletion analysis of the STP-rich domain 
showed complete abolishment of DAF activity (Coyne et al., 1992) and variations 
in the exon encoding for the GPI-anchor attachment site may contribute towards 
the paroxysmal nocturnal hemoglobinuria disorder (Yazer et al., 2006). In the 
current study, MG patients exhibited no mutations in the exons encoding the 
critical domains of the DAF gene indicating that these protein domains are intact 
and probably able to perform their functions. 
Promoter SNPs have been shown to influence variation in gene 
expression in Drosophila development, teleost fish populations and in human 
lymphoblastoid cell lines (Rifkin et al., 2003; Oleksiak et al., 2002; Cheung et al., 
2003). In the past few decades these SNPs have also been implicated in 
susceptibility of individuals to complex diseases (Knight, 2004). We identified two 
SNPs in the 5`-regulatory region of the DAF gene, namely c.-244_-243insA and 
c.-198C>G. Both SNPs have previously been reported in African-American and 
European control populations and are designated as rs28371585 for the c.-244_-
243insA (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28371585) 
and rs28371586 for the c.-198C>G SNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28371586). 











present study, the Black and Mixed-Ancestry (M/A) controls independently 
showed similar allele frequencies for both SNPs to that found in the African 
American controls. Also, the South African White MG patients and controls, 
showed very low frequencies of the SNPs similar to the results from European 
control samples.  
 The c.-244_-243insA does not show an association with either MG or the 
development of ocular muscle pareses. It is therefore likely that this SNP is a 
common polymorphism in the 5` regulatory region of the DAF gene and may be 
nonpathogenic.  
Overall, the c.-198C>G SNP showed no significant association with MG 
compared with controls. However, when the patients were categorised on the 
basis of severity of the EOM, a significant association was seen between the c.-
198C>G SNP and patients developing the treatment-resistant EOM phenotype. It 
appears that the Black (OR = 12.9, p = 0.006) and M/A (OR = 6.2, p = 0.022) 
subjects with the SNP are more susceptible to developing MG with at least one 
or more EOM dysfunction compared to the racially matched controls. An even 
stronger association is observed between the c.-198C>G SNP and this clinical 
phenotype when the Black and M/A patient categories are combined in an 
African ancestry group (OR of 8.6 (p = 0.0003)). These findings suggest that the 
c.-198C>G SNP may be a susceptibility allele for the development of the severe 
EOM phenotype associated with MG. Alternatively, the SNP may not be the 
susceptibility allele but its association with this MG phenotype may imply that it is 
in linkage disequilibrium with an, as yet, unknown disease-causing allele on the 
same chromosome. 
 
4.2 Regulatory effect of the DAF c.-198C>G SNP 
The initial hypothesis of this study was that DAF expression may be lower than 











muscles vulnerable to complement damage. The activation of the basal DAF 
promoter activity was therefore unexpected. One possible explanation for this 
upregulation may be that during the design of the reporter gene construct other 
unexpected variations in the sequence may have been introduced. However, the 
sequences were verified after site-directed mutagenesis, thus excluding this 
possibility. Another possible explanation is that the reporter gene assays are 
highly dependent on biological systems in which the experiments are performed 
(Knight, 2004). In this study the promoter reporter assays were performed in 
COS-7 monkey epithelial cells, HT1080 human fibrosarcoma cells, and C2C12 
mouse myoblast cells, all of which may not be representative of the EOM system. 
In the absence of a better representative of the in vivo EOM tissue, basal DAF 
mRNA expression was analysed in three lymphoblastoid cell lines derived from 
MG patients with the c.-198C>G SNP. These results showed that DAF was 
upregulated in the SNP cell lines compared to the controls. It is known that 
constitutive DAF expression is tissue- and cell-type specific (Lin et al., 2001; 
Thomas and Lublin, 1993) and that it is regulated by various cytokines, 
prostaglandins and tissue-specific factors (reviewed in Cauvi et al., 2006). 
Therefore, basal transcription in the MG individuals with the SNP may 
theoretically be influenced by certain circumstances that may differ from an in 
vitro situation.  
The lack of variation in DAF mRNA expression in peripheral blood from 
patients and controls was thought to be the effect of the immunosuppressive 
drugs. It was reasoned that lymphoblastoid cell lines (LCLs) would be a more 
appropriate drug-free system for studying endogenous DAF expression. LCLs, 
which express endogenous DAF (Tate et al., 1989), were established from B 
lymphocytes of individuals with and without the c.-198C>G SNP, using EBV-
transformation. The EBV infects the B lymphocytes and transforms them by 
changing cellular gene expression through incorporation and expression of 
several viral proteins capable of causing continuous B-cell proliferation 
(Rickinson and Kieff, 2001). Surprisingly, when comparing the c.-198C>G SNP to 











increased level of expression in three lymphoblastoid cell lines, with an exception 
of one cell line (MG4) (Figure 3.12). These results were similar to the luciferase 
reporter assays which showed upregulation of basal transcription of the DAF 
reporter vector in the presence of the c.-198C>G SNP. Unexpectedly, DAF 
mRNA levels were also upregulated in the WT/MG lymphoblasts (without the 
SNP), which may implicate some other, as yet, unknown factor. 
Studies have shown that SNPs in the 5` regulatory region of a gene can 
be either cis-acting or trans-acting (Tegeder et al., 2006). The cis-acting SNPs 
influence the gene expression of that specific gene whereas trans-acting SNPs 
may affect the expression of another gene (Knight, 2004). The c.-198C>G SNP 
may be a cis-acting regulatory SNP as it affects the transcriptional regulation of 
the DAF gene. Interestingly, the SNP also appears to be in a region that has 
been shown to harbour several transcriptional control elements in both humans 
and mice. Ewulonu et al. (1991) demonstrated that there are inhibitory regulatory 
sequences in the DAF promoter and showed that DAF activity can be reduced to 
11% or less in COS cells if the sequence between -159 and -242 from the start 
codon is deleted. In addition, deletion of the region between -207 and -77 in the 
human DAF gene resulted in approximately 75% loss of transcriptional activity 
(Thomas and Lublin, 1993). In the mouse daf1 gene, this region was also shown 
to contain enhancer elements similar to those in the human DAF (Cauvi et al., 
2006). Therefore, a change in one base in the regulatory region, such as the c.-
198C>G SNP, may lead to a gain of an enhancer or loss of an inhibitory element, 
possibly resulting in the activation in DAF promoter activity. 
In this study, computational methods predicted the loss of a Sp1 binding 
site in the region of the c.-198C>G SNP. The Sp1 transcription factor is a 
member of the four small proteins Sp-family of transcription factors consisting of 
Sp1, Sp2, Sp3 and Sp4 that contain three zinc fingers near the C-terminus and is 
ubiquitously expressed (Suske, 1999). The Sp1 transcription factor has been 
shown to activate gene promoters through the GC-boxes (Pascal and Tjian, 











genes such as mouse Daf1 gene, house-keeping genes, tissue-specific genes 
and genes involved in growth regulation (Suske, 1999; Philipsen and Suske, 
1999; Cook et al., 1998). There is evidence that clusters of Sp1 binding sites are 
required for efficient transcription of the TATA-less promoter for insulin-like 
growth-factor binding-2 protein in rats (Boisclair et al., 1993).  
 
4.3 Loss of the Sp1 site affects LPS-induced DAF upregulation in 
humans  
In mouse studies, Cauvi et al. (2006) identified three Sp1 binding sites in the 
DAF1 promoter (+1 to -619) and deletion of the most distal Sp1 site (equivalent 
to that lost in this study) did not have a significant effect on the basal transcription 
of the daf1 gene. Interestingly, in the same study however, deletion of the Sp1 
site which is equivalent to the putative Sp1 site at c.-198C>G SNP showed 
upregulation of luciferase reporter activity compared to the wild type in a murine 
B-cell line (M12.4). In the present study, transient co-transfections with a Sp1 
expression vector showed a similar effect on both the WT- and Mut-DAF 
promoter constructs, suggesting that the Sp1 site at -198 position may not be 
important for basal transcription. It is also possible that endogenous Sp1 is 
present in great abundance and therefore masks the effect of transfected Sp1 
protein. 
 Various complement regulatory proteins, such as DAF, are reportedly 
upregulated in response to LPS in endometrial cells (Iborra et al., 2003) and rat 
smooth muscle cells (Li et al., 1999). Cauvi et al. (2006) showed that this LPS 
upregulation is mediated through Sp1 binding sites in B-cells and macrophages, 
but not fibroblasts, suggesting tissue specificity of LPS-induced DAF 
upregulation. Sequential deletion of Sp1 sites, particularly those close to the 
transcription start site showed loss of upregulation in response to LPS (Cauvi et 
al., 2006). Similarly, the results of this study show that lymphoblasts of 











3.15A). However, DAF mRNA and protein levels were not responsive to LPS in 
the lymphoblastoid cells of the MG patients with the c.-198C>G SNP (Figure 
3.15). These results suggest that the loss of the putative Sp1 binding site at c.-
198C>G may affect the upregulation of DAF in response to LPS providing further 
supportive evidence that the c.-198C>G SNP has functional significance.  
 LPS is a component of the cell wall of gram-negative bacteria that has the 
ability to initiate inflammatory responses (Antonicelli et al., 2004). Activation of 
the early proteins of the classical and alternative pathways of complement has 
been shown to produce proteolytic peptides with inflammatory activities (Frank, 
1995), and activation of the late complement proteins leads to the formation of 
terminal complement complexes which associate with inflammatory cells and can 
be damaging to the host tissues (reviewed in Lang et al., 1997). These terminal 
complement complexes together with C3 fragments have been observed at 
NMJs in affected muscles of MG (Sahashi et al., 1980). As a potent inhibitor of 
C3 and C5 convertases, the inability of DAF to upregulate under inflammatory 
conditions, such as mimicked by LPS, may indicate that the MG patients with the 
c.-198C>G SNP are unable to express adequate membrane-bound DAF 
resulting in severe complement mediated injury at the EOM in such 
circumstances. Indeed, in the DAF knock-out mouse model, daf1-deficient mice 
were more susceptible to EAMG induction and suffered more severe 
complement mediated muscle damage compared to wild-type mice (Lin et al., 
2002). 
There is evidence to show that DAF has another function apart from 
complement. Liu et al. (2005) showed that daf1 deficiency in mice led to the 
development of enhanced T-cell immune responses and Heeger et al. (2005) 
also showed that the absence of Daf resulted in loss of normal T-cell regulation 
which in turn caused local inflammation. In addition, T-cell immunity has also 
been shown to be involved in the pathogenicity of MG, as mice that lacked CD4+ 
T-cell receptors did not develop EAMG (Kaul et al., 1994). We therefore 











immune-mediated damage to EOM in MG independent from its effect on 
complement. 
 
4.4 Limitations to the study 
The tissue specificity of DAF regulation in the EOMs could not be demonstrated 
as it is impossible to obtain EOMs from the MG patients specifically at an active 
stage of the disease. The COS-7, HT1080, C2C12 and human lymphoblastoid 
cell lines may not be ideal for illustrating the effect of the DAF c.-198C>G SNP in 
the human EOM environment in vivo.  
In this study the loss of the Sp1 transcription factor binding site due to the 
c.-198C>G SNP was investigated. This polymorphism however also resulted in a 
gain of a putative NF-KB transcription factor binding site which has been 
implicated in inflammatory conditions. However, due to time constraints the gain 
of the NF-kB binding site could not be investigated.  
Ideally the effect of the SNP on DAF expression should be examined in 
MG patients before exposure to therapeutic drugs which probably influences 
gene expression. Unfortunately the project was initiated during the course of 
treatment and thus this was not possible. 
 
4.5 Conclusion 
This project focused on investigating a “complement hypothesis” in which 
reduced DAF expression results in a treatment-resistant EOM phenotype in a 
subgroup of MG patients. The experimental findings reported in this thesis 
contribute considerably to the existing knowledge of MG pathogenecity. For the 
first time, it is shown that a SNP in the regulatory region of the human DAF gene 
influences DAF expression. The observed upregulation of the gene expression 
contradicted the initial hypothesis, probably because the experimental conditions 
were not representative of the in vivo EOM tissue. However, in conditions 
mimicking the inflammatory environment of an autoimmune disorder DAF 
expression was down-regulated as hypothesised. Thus it can be deduced that 











protection of tissues against complement-mediated damage. Current treatments 
are aimed at reducing the production of auto-antibodies but this is not specifically 
targeting the prevention of complement mediated damage. It therefore seems 
prudent to suggest that in MG patients who develop a treatment-resistant EOM 
phenotype and who are found to have the c.-198C>G SNP, additional anti-
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APPENDIX A – General Recipes and Reagents 
 
Amplification of DNA 
constructs 
Luria broth (LB) 
10g Bacto-tryptone 
5g Yeast extract 
10g Sodium Chloride 
Make up to 1 litre with dH20 





5g Yeast extract 
10g Sodium chloride 
15g agar 
Make up to 1 litre with dH20 




2% Agarose gel 
1g agarose powder 
50ml 1xTBE 
Heat solution to dissolve agarose 
Cool to approximately 50ºC 
Pour and allow to set 
 
10x Tris-Borate-EDTA (TBE) 
electrophoresis buffer 
0.89M Tris 
0.89M Boric acid 
0.02M EDTA 
Make up to 1 liter with dH2O 
For use, dilute to 1x 
 
Agarose loading dye 
0.25% bromophenol blue (0.125g) 
40% sucrose (20g) 




Make a 1 in 2000 of loading dye 
RNA extraction 
DEPC-treatment 
0.1% DEPC in distilled water 
Stir for 30 minutes 
Soak pipette tips and micro-
centrifuge tubes in DEPC-treated 
water overnight 







Make up to 150ml in 1x PBS 
Filter trough 0.22µM filter 






0.2g KH2PO4  
0.5G Trypsin 
0.2g EDTA 
Make up to 1 liter with dH2O 
pH to 7.4 
Filter sterilize through 0.22 µM filter 





0.8g N-N-methylene bisacrylamide 
Make up to 100ml with dH20 
Store at 4ºC covered in foil 
 
10% Ammonium persulphate 
(APS) 
0.1g ammonium persulphate 













10% Sodium dodecyl sulphate 
(SDS) 
100g SDS 
Make up to 1 liter with dH20 
pH to 7.2 
Store at room temperature 
 
Antibodies (Primary) 
BRIC216 Mouse monoclonal anti-
DAF  1 in 100 in 5% skim milk 
P38 Rabbit polyclonal  
1 in 5000 in 1x PBS/0.1% Tween 
 
Antibodies (Secondary) 
Goat anti-mouse IgG HRP 
conjugated 
 1 in 5000 in 5% skim milk 
Goat anti-rabbit IgG HRP conjugated 
 1:5000 in skim milk  
 
5% Blocking buffer 
5% powder skim milk (w/v) 
Make up to 50ml with 1x PBS/0.1% 
Tween 
 




Make up to 1 liter with dH20 
For use, dilute to 1x 
 
10x Transfer buffer 
144g Glycine 
38g Tris 
Make up to 1 liter with dH20 
 
1x Transfer buffer 
100ml 10x transfer buffer 
700ml dH20 
200ml isopropanol 
Mix well with magnetic stirrer 
Store at 4ºC 
 
Membrane stripping buffer 
100mM β-mercaptoethanol 
2% SDS 
62.5mM Tris-HCl pH6.7 
 






Make up to 1 liter, pH to 6.9 and 
autoclave 
For use, dilute to 1x 
 
1x PBS/0.1% Tween 
1x PBS made up to 1 liter 
1ml Tween 
Stir for half an hour with stirrer bar 
 
10x Protease inhibitor 




5x Protein loading dye for non-
reducing conditions 
10% glycerol 
0.25M Tris-Cl pH 6.8 
3mg Bromophenol blue 
Store at room temperature 
 
Non-reducing protein extraction 
buffer 
150mM NaCl 
1.0% NP-40 (Triton X-100 can be 
substituted for NP-40) 
50mM Tris, pH8.0 
Store at 4ºC 
 
Extraction buffer for protein 
harvesting 
Per 1ml of extraction buffer: 

















8% Resolving SDS-PAGE (10ml) 
2.7ml 30% Acrylamide:bis 
2.5ml 1.5M Tris (pH8.8) 
100µl 10% SDS 




5% Stacking gel (4ml) 
650µl 30% Acrylamide:bis 
500µl 1.5M Tris (pH6.8) 
























































































APPENDIX B – Molecular weight markers 
 
 













peqGold Prestained Protein 




























APPENDIX C – Protocol for establishing the standard curve (used 
gDAF as an example) 
 
The equations given below were used to calculate the number of moles that 
contain 1x106  molecules/mol: 
Avogadro’s number = 6.022 x 1023 molecules per mole 
Pmoles of dsDNA = (ug dsDNA) (1515) 
   Produce size in bp 
 
We calculate the number of moles that contain 1x106 molecules as follows: 
 
1x106 molecules 
6.022 x 1023 molecules per mole 
= 1.66x10-18 moles 
= 1.66x10-6 pmoles 
i.e. 1.66x10-6 pmoles contain 1x106 molecules. 
 
Since Pmoles of dsDNA = (ug dsDNA) (1515) 
    Produce size in bp 
Then ug of dsDNA = (Pmoles of dsDNA) (Produce size in bp) 
    1515 
Product of gDAF = 322bp 
 
That is then ug of dsDNA = (1.66x10-6 pmoles) (322) 
    1515 
= 3.528x10-7 ug of dsDNA 
= 3.528x10-4 ng of dsDNA 
= 0.3528 pg of dsDNA 
Therefore the purified standard PCR 
product for gDAF was diluted to 















APPENDIX D - Technical issues 
Trouble-shooting and optimizing PCR amplification for the DAF promoter 
region 
PCR amplification of DAF promoter region required optimization by trying 
different methods and changing the reagents. Initially, the PCR reaction for this 
region was carried out using the GoTaq polymerase enzyme following the 
conditions stated in Chapter 2. The experiments produced good results but later, 
for no apparent reason, failed. Firstly, we used fresh reagents including the 
primers, dNTPs, buffer and sterile water, but without success. Secondly, we tried 
increasing the concentration of the DNA template, followed by increasing the 
concentrations of the dNTPs and the GoTaq polymerase but with no success. 
Thirdly, we ran duplicate PCR reactions using reagents and a machine from 
another laboratory, but still failed. Using an alternative Bioline BioTaq 
polymerase and buffer did not produce any better results. Finally, we optimized 
the PCR reactions by using Failsafe buffer (Epicentre Biotechnologies, USA) 
which contained the dNTPs, the MgCl2 and the buffer already mixed.  
 
qRT-PCR method for quantifying DAF mRNA 
Initially we experienced problems obtaining a smooth peak for the melting curve 
for the GUS gene. We optimized this by increasing the amount of the primers 
and the cDNA template. The best results were achieved by also changing certain 
conditions such as reducing the amount of holding time during the cycling from 
30 seconds to 5 seconds.  
 There are two ways in which qRT-PCR quantification can be performed as 
explained in Chapter 2. Initially, we used the relative quantification method using 
the 2-ddCT calculation. However, we obtained varying results for DAF mRNA 
expression from healthy controls which complicated interpretation of results from 
the MG patients. An alternative and adjunct method is to construct standard 
curves for each gene (Chapter 3) using absolute amounts of the standard 











one standard dilution which made it possible for us to compare the experiments 
done at different times. The two methods of quantification gave us similar trend 
of the results.  
Initially we used a second house keeping gene, GAPDH. However, similar 
results were obtained as with GUS house keeping gene.  
 
Transient transfection experiment 
C2C12 muscle cells were allowed to differentiate for a longer period of time so as 
to obtain mature muscle cells, a better representative of the tissue in which the 
MG condition occurs. These cells have been shown to start differentiating as 
soon as the serum is reduced in the medium and after 24 hours the cells start to 
fuse longitudinally resulting in long muscle fibers (Kubo, 1991). We experienced 
difficulties with reproducing results in the transfections of C2C12 cells that were 
allowed to differentiate for 10 days. From the few readings obtained, the 
luciferase activity in these cells was very low and no visible differences were 
observed between the WT- and Mut-DAF. This may have been as a result of the 
cells failing to contain the transfected DNA plasmid for so many days or that 
there was low transfection efficiency in these cells. 
 
Western blot analysis 
When we acquired the BRIC 216 DAF antibody (International Blood Group 
Reference Laboratory, UK) they did not provide clear conditions under which the 
antibody recognizes the DAF protein. Since most antibodies recognize reduced 
and denatured protein and are used under reducing and denaturing conditions, 
we firstly ran a denaturing SDS gel using reduced protein. We could not detect 
any protein under these conditions. We then tried to optimize this by varying the 
amounts of protein and also the concentration of the BRIC 216 antibody used to 
detect the DAF protein. Unfortunately, none of these conditions gave us any 
results. 
 The next experiment we tried was to run a non-reducing and non-












excluded SDS, the samples were not heated and the loading dye did not contain 
and protein denaturing reagents such as SDS, ß-mecaptoethanol and DTT. 
Additionally, we prepared a non-denaturing gel and running buffer by leaving 
SDS out. However, no results were obtained from this experiment. 
 Finally, we discovered that the BRIC 216 antibody recognizes the DAF 
protein under nor-reducing condition (without ß-mecaptoethanol and DTT) but on 
a denaturing gel (with SDS). Under these conditions we were able to detect the 
DAF protein. 
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